[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Institut National de la Santé Et de la Recherche Médicale, France\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":650},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,84,0,25,[9,43,75,98,124,152,177,199,226,254,286,313,341,372,397,419,439,461,485,511,534,557,583,604,631],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":25,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100645346","european-cystinosis-cohort-2-100645346",false,"NCT07680751","European Cystinosis Cohort 2","RaDiCo-ECYSCO2","Inclusion Criteria:\n\n* Confirmed diagnosis of cystinosis based on leukocyte cystine measurement, presence of corneal cystine crystals, and\u002For molecular genetic diagnosis\n* Signed informed consent obtained from the patient or legal representative\n\nExclusion Criteria:\n\n* Patients unable to provide informed consent or without a legal representative when required\n* No other specific exclusion criteria; patients with associated diseases may be included","ALL",{"count":19,"type":20},250,"ESTIMATED","OBSERVATIONAL","This European observational cohort follows patients with cystinosis, a rare lysosomal storage disease caused by CTNS mutations leading to cystine accumulation and multisystem involvement. It aims to describe the long-term clinical course under current treatments, focusing on renal and extra-renal complications, survival, and quality of life. It also evaluates treatment effects and explores biomarkers, including inflammatory markers, with biobanking for future research.",[24],"Cystinosis",[24,26,27,28,29],"Rare disease cohort","CTNS mutation","European Study","Cysteamine treatment","NOT_YET_RECRUITING","2026-06-26",{"date":33,"type":34},"2026-07-02","ACTUAL",{"date":36,"type":20},"2026-07-01",{"date":38,"type":20},"2028-03-01",{"name":40,"class":41},"Institut National de la Santé Et de la Recherche Médicale, France","OTHER_GOV",1,{"id":44,"slug":45,"hasResults":12,"nctId":46,"briefTitle":47,"officialTitle":47,"acronym":48,"eligibilityCriteria":49,"healthyVolunteers":50,"sex":17,"minAge":51,"maxAge":52,"enrollmentInfo":53,"targetDuration":4,"studyType":55,"phases":56,"briefSummary":58,"conditions":59,"keywords":63,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":42},"100634401","precarity-and-reduction-of-its-impact-on-the-mental-health-of-health-students-100634401","NCT07539207","Precarity and Reduction of Its Impact on the Mental Health of Health Students","PRISMES","Inclusion Criteria:\n\n* Enrollment as a health student at the Faculty of Health, Université de Rouen Normandie (any program or discipline).\n\nAge between 18 and 30 years.\n\nMeet at least one of the following three financial vulnerability criteria:\n\nInsufficient monthly funds to cover basic living expenses. Recurrent monthly bank overdraft. Frequent omission of food purchases due to financial constraints. Affiliation with a social security scheme or beneficiary of such a scheme\n\nExclusion Criteria:\n\n* Participants meeting any of the following criteria will be excluded:\n\nCurrently receiving, or having received in the past 12 months, psychological or sophrology follow-up.\n\nCurrently treated for, or having been treated in the past 12 months for, anxiety or depression.",true,"18 Years","30 Years",{"count":54,"type":20},110,"INTERVENTIONAL",[57],"NA","Student financial insecurity has become a major public health and societal issue affecting a growing proportion of young adults in higher education, exacerbated by the COVID-19 pandemic and more recently by inflation. Health students may be particularly exposed because of the demanding and lengthy nature of their training, often combined with limited opportunities for paid work due to hospital placements and academic workload. A national study conducted in 2024 by the Unit Institut national de la santé et de la recherche médicale U1073 under the supervision of the Conférence Nationale des Doyens de Médecine among more than 12,000 health students showed that 12% experienced severe financial insecurity, characterized by insufficient monthly resources, recurrent bank overdrafts, and frequent food deprivation, while 20% reported moderate insecurity. Financial insecurity was strongly associated with anxiety, depression, and emotional exhaustion, while vulnerable students were also more likely to forgo healthcare, including psychological consultations, for financial reasons. This vicious circle between financial hardship and mental health may compromise academic success and justifies targeted intervention.\n\nAlthough support systems such as Santé Psy Étudiant and free psychological consultations at the faculty already exist, they remain underused because of stigma, insufficient information, or perceived barriers to access. The PRISMES project proposes a participatory, adaptive, and real-world intervention designed to improve mental health support for financially vulnerable health students.\n\nStudents directly participate in the co-construction of interventions together with researchers, student associations, health professionals, academic representatives, and a sociologist involved in understanding social determinants, mental health representations, and barriers to participation. Three intervention formats will initially be proposed, Three types of interventions are offered to students. Intervention I consists of four individual psychological consultations. Intervention II includes two collective workshops focused on stress and budget management, combined with two sophrology sessions. Intervention III comprises one psychological consultation and two collective workshops on stress and budget management.. This non-randomized design reflects real-life implementation conditions and improves future transferability.\n\nThe main objective is to provide concrete support to financially vulnerable students by improving well-being, mental health, and knowledge of available support systems. Secondary objectives are to evaluate intervention effects on anxiety, depression, stress, quality of life, and emotional exhaustion, to adapt interventions according to feedback, and to improve awareness and use of social and health support services.\n\nA mixed-method design will combine quantitative and qualitative data. Quantitative assessments will be conducted monthly during the three months following the first intervention and again three months after the final intervention. Validated questionnaires will assess perceived stress (Cohen scale), anxiety and depression (HAD score), quality of life, and emotional exhaustion (MBI-SS). Qualitative interviews and focus groups conducted at the end of the intervention will explore perceived benefits, barriers, and implementation factors among students and professionals.\n\nThe adaptive design allows continuous adjustment according to interim findings. For example, if attendance is limited by timetable constraints, sessions may be rescheduled. Feedback loops involving participants and stakeholders will guide iterative improvement.\n\nEligible participants are health students aged 18-30 enrolled at Université de Rouen Normandie presenting at least one indicator of financial insecurity: insufficient monthly resources, recurrent overdraft, or frequent food deprivation. Students currently receiving psychological follow-up are excluded.\n\nAssuming a reduction in anxiety prevalence from 55% to 45%, 88 participants are required; with 20% loss to follow-up, 110 students will be included. Among approximately 4,500 health students in Rouen, about 540 are estimated to experience severe insecurity and 900 moderate insecurity, ensuring strong feasibility. PRISMES aims to generate directly transferable recommendations for university support policies and improve resilience, well-being, and academic success.",[60,61,62],"Mental Health (Depression)","Mental Health","Quality of Lifte",[64,65,66],"university student","economic precarity","mental health","2026-06-09",{"date":69,"type":34},"2026-06-11",{"date":71,"type":20},"2026-09-15",{"date":73,"type":20},"2027-09-30",{"name":40,"class":41},{"id":76,"slug":77,"hasResults":12,"nctId":78,"briefTitle":79,"officialTitle":79,"acronym":80,"eligibilityCriteria":81,"healthyVolunteers":50,"sex":17,"minAge":51,"maxAge":4,"enrollmentInfo":82,"targetDuration":4,"studyType":55,"phases":84,"briefSummary":85,"conditions":86,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":42},"100643819","investigating-vascular-properties-of-hemi-and-spg-signals-in-individuals-with-or-at-risk-for-chronic-kidney-disease-100643819","NCT07604922","Investigating Vascular Properties of HEMI and SPG Signals in Individuals With or at Risk for Chronic Kidney Disease","STIMULUS-CKD","Inclusion Criteria:\n\n* Common Inclusion Criteria:\n\n  * Adults aged over 18 years, of both sexes\n  * Patients eligible for or affiliated with a social security scheme\n  * Patients who have provided written informed consent to participate in the study\n\nCommon Exclusion Criteria:\n\n* Inability to give informed consent\n* Persons under legal protection (guardianship, trusteeship, or court protection)\n* Language barrier or psychological refusal to read the information\n* Medical conditions with a life expectancy \\\u003C 1 year according to clinical judgment\n* Ongoing participation restriction due to another clinical research study\n* Pregnant women (due to physiological hemodynamic changes in blood pressure and arterial stiffness during pregnancy)\n* Cardiac arrhythmias: current atrial fibrillation or high-degree atrioventricular block\n\nExclusion Criteria:\n\n* Hypertension Group\n\n  * Inclusion: Prior diagnosis of arterial hypertension\n  * Stable cardiovascular treatment in the previous 1 month\n  * Exclusion:\n\n    * CKD with GFR \\\u003C60 mL\u002Fmin\n    * ACR \\> 30 mg\u002Fmmol\n    * Type 2 diabetes Type 2 Diabetes Group\n  * Inclusion:\n  * Prior diagnosis of type 2 diabetes\n  * Stable cardiovascular treatment in the previous 1 month\n  * Exclusion:\n\n    * CKD with GFR \\\u003C 60 mL\u002Fmin\n    * ACR \\> 30 mg\u002Fmmol Moderate CKD Group\n  * Inclusion:\n  * Moderate CKD (eGFR between 30 and 60 mL\u002Fmin) (CKD-EPI)\n  * Patients scheduled for arterial stiffness assessment as part of routine care\n  * Stable cardiovascular treatment in the previous 1 month\n  * Exclusion:\n  * No specific exclusion criteria beyond common exclusions Severe CKD Group\n  * Inclusion:\n\n    * Severe CKD (GFR \\\u003C 30 mL\u002Fmin for ≥ 2 months)\n    * Patients scheduled for arterial stiffness assessment as part of routine care\n    * Stable cardiovascular treatment the previous 1 month\n  * Exclusion: No specific exclusion criteria beyond common exclusions20 \u002F 48 C25-07\\_Protocole\\_ V1.0\\_01.12.2025 Healthy Volunteers Group\n  * Inclusion: No documented chronic disease\n  * Exclusion:\n\n    * Moderate or severe CKD (GFR \\\u003C 60 mL\u002Fmin) (CKD-EPI)\n    * Hypertension\n    * Type 2 diabetes\n    * Stable cardiovascular treatment in the previous 1 month",{"count":83,"type":20},165,[57],"This prospective, single-center clinical investigation conducted in France will evaluate two non-invasive investigational devices (HEMI and SPG-NINOX) designed to assess microcirculation in adults. The study will include 165 participants divided into five groups (33 per group): healthy volunteers, patients with hypertension without chronic kidney disease (CKD), patients with type 2 diabetes without CKD, patients with moderate CKD, and patients with severe CKD. The primary objective is to compare baseline small vessel pressure measured with the HEMI (Multi-spectral optical system for microcirculation hemodynamics) device across groups in order to identify microvascular alterations associated with cardiometabolic and renal disease. Secondary objectives include assessment of microvascular responses after post-ischemic hyperemia, evaluation of SPG-derived (Speckle plethysmography) small vessel flow and volume parameters, comparison with reference vascular measurements (including SphygmoCor and ultra-high frequency ultrasound), and evaluation of feasibility, acceptability, and measurement reproducibility. Participation is non-randomized, based on participants' pre-existing clinical condition, and study procedures are non-invasive with an expected visit duration of approximately 60 minutes.",[87,88,89],"Chronic Kidney Disease","Hypertension (HTN)","Type 2 Diabetes Mellitus (T2DM)","2026-06-04",{"date":92,"type":34},"2026-06-08",{"date":94,"type":20},"2026-06-15",{"date":96,"type":20},"2028-09-15",{"name":40,"class":41},{"id":99,"slug":100,"hasResults":12,"nctId":101,"briefTitle":102,"officialTitle":102,"acronym":103,"eligibilityCriteria":104,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":105,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":107,"conditions":108,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":116,"lastUpdatePostDateStruct":117,"startDateStruct":119,"completionDateStruct":121,"leadSponsor":123,"locationsCount":42},"100639061","virological-surveillance-of-acute-respiratory-infection-in-primary-health-care-in-metropolitan-france-100639061","NCT07599449","Virological Surveillance of Acute Respiratory Infection in Primary Health Care in Metropolitan France","RS-viro IRA","Inclusion Criteria:\n\n* be seen by a general practitioner or pediatrician participating in the Sentinelles surveillance program;\n* between week 40 (late September-early October) and week 15 (mid-April) of each year\n* have an acute respiratory infection (ARI) as defined below: Sudden onset of fever (or feeling of fever) and respiratory symptoms\n* have given oral consent to participate in this monitoring or, in the case of minors, oral consent given by the child's legal guardian(s) present at the consultation\n\nExclusion Criteria:\n\n* a person who is subject to a court-ordered protective measure;\n* a person who is under guardianship or conservatorship, unless accompanied by their legal guardian or unless the legal guardian objects to their participation;\n* a person who is not in a condition to receive information or give consent.",{"count":106,"type":20},25000,"Every year in the fall and winter, numerous respiratory viruses (such as influenza viruses, SARS-CoV-2 (COVID-19), RSV, rhinovirus, and metapneumovirus) circulate in mainland France, causing acute respiratory infections (ARIs). These viruses can cause epidemics of varying severity, requiring close monitoring to determine their circulation levels and adapt public health measures accordingly. In France, ARI surveillance relies on two networks: the Sentinelles network in primary care and the RENAL network in hospitals. The Sentinelles surveillance is conducted in collaboration with Santé publique France, the National Reference Center for Respiratory Infection Viruses (Institut Pasteur and Hospices Civils de Lyon), and the University of Corsica. As part of the virological surveillance of ARIs, Sentinelles physicians are asked to collect nasopharyngeal swabs or saliva samples from a sample of patients presenting with an ARI during their clinic visits. This surveillance makes it possible to identify respiratory viruses circulating in primary care (general practice and pediatrics), to describe confirmed cases for each of the circulating viruses, and to estimate the impact of each on general practice. This surveillance also allows for the evaluation of the effectiveness of vaccines against influenza and COVID-19.",[109,110,111,112,113,114,115],"Respiratory Tract Infections (RTI)","Influenza -Like Illness","Influenza","COVID - 19","RSV Infections","Rhinovirus Infection","Metapneumovirus Infection","2026-06-03",{"date":118,"type":34},"2026-06-05",{"date":120,"type":20},"2026-05-15",{"date":122,"type":20},"2031-05-20",{"name":40,"class":41},{"id":125,"slug":126,"hasResults":12,"nctId":127,"briefTitle":128,"officialTitle":129,"acronym":130,"eligibilityCriteria":131,"healthyVolunteers":50,"sex":17,"minAge":132,"maxAge":4,"enrollmentInfo":133,"targetDuration":4,"studyType":55,"phases":135,"briefSummary":136,"conditions":137,"keywords":140,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":116,"lastUpdatePostDateStruct":146,"startDateStruct":147,"completionDateStruct":149,"leadSponsor":151,"locationsCount":42},"100616869","genes-and-autism---induced-pluripotent-stem-cells-100616869","NCT07311213","GENES AND AUTISM - Induced Pluripotent Stem Cells","EXPLORATIONS CELLULAIRES - CELLULES PLURIPOTENTES INDUITES DES SUJETS PRESENTANT UN TSA, DE LEURS APPARENTES, ET DE TEMOINS","IPSC","Inclusion Criteria:\n\n● For all participants :\n\n* 1\\) Be Included in the \"Genes and Autism\" protocol (C07-33 or C16-89).\n* 2\\) Affiliated to the social insurance, Universal Health Coverage or any equivalent system.\n\n  →As a Reminder : C07-33 inclusion criteria\n\n  ● Participants with ASD.\n* 1\\) Autistic patients must meet the diagnostic criteria of DSM-IV \\[American Psychiatric Association, 1994\\] and the criteria of ADI-R (Autism Diagnostic Interview-Revised, Lord et al., 1994) and ADOS for autism.\n\n..Or.. Patients with Asperger's syndrome must meet the DSM-IV criteria as well as the ASDI criteria for Asperger's syndrome (Asperger Syndrome Diagnostic Interview, Gillberg et al., 2001) and the ADOS for autism spectrum disorders.\n\n..Or.. Patients with ASD must meet diagnostic criteria of DSM-IV and ADOS criteria for autism spectrum disorders\n\n* 2\\) Be at least 2 years old, with no upper age limit\n* 3\\) Somatic state compatible with blood test\n\n  ● Adult controls and adult relatives of controls\n* 1\\) Be between 18 and 65 years old\n* 2\\) Somatic and intellectual state compatible with blood test\n\n  ● Controls with mental retardation\n* 1\\) Minimum age of 2 yearsIQ \\\u003C 70Child controls\n* 2\\) Minimum age of 2 years\n\n  →As a Reminder : inclusion criteria C16-89\n\n  ● Probands with ASD\n* 1\\) Meet the diagnostic criteria for ASD of the of DSM-5 \\[American Psychiatric Association, 2012\\]. The diagnosis will be based on a consensus between the clinical expertise of expert clinicians, the scores of the Autism Diagnostic Interview-Revised (ADI-R) (Lord et al, 2003) and those of the Autism Diagnosis Observational Scale (ADOS-2) (Lord et al, 1994)\n* 2\\) Be at least 24 months old with no upper age limit\n* 3\\) Somatic state compatible with a blood test\n* 4\\) Affiliation to the Social Insurance\n* 5\\) Signature of informed consent by the applicant or by the holders of parental authority if the subject is a minor or by the guardian if the subject is under guardianship\n\n  ● Controls wihout ASD\n* 1\\) At least 24 months old\n* 2\\) Somatic and Intellectual state compatible with a blood test\n* 3\\) Affiliation in the Social Insurance\n* 4\\) Signature of informed consent by the subject or by holders of parental authority if the subject is a minor, or by the guardian if the subject is under guardianship\n\n  ● Relatives of the probands with ASD or of controls without ASD\n* 1\\) At least 24 months old\n* 2\\) Somatic and intellectual state compatible with blood test\n* 3\\) Affiliation to the Social Insurance\n* 4\\) Signature of informed consent by the subject or by the holders of parental authority if the subject is a minor or by the guardian if the subject is under guardianship\n\nExclusion Criteria:\n\n* For all participants\n\n  * 1\\) Refusal to have a blood test\n  * 2\\) Medical illness (including psychiatric disorder) not yet fully stabilised and making participation in the study impossible\n  * 3\\) Person subject to a mesure of lagal protection\n  * 4\\) Known serology : VIH+ or VBH+ or VCH+\n\n    * As a reminder : exclusion criteria C07-33\n  * 1\\) For all participants : Severe Intelectual Deficiency (IQ,35 or developmental age \\\u003C18 months)\n  * 2\\) Controls : Neurological or psychiatric history other than mental retardation\n\n    o Psychiatric history, except for mental retardation, assessed using the DIGS (Diagnostic Interview for Genetic Studies, Nurnberger et al., 1994) for adults or the Kiddie-SADS (Kiddie Schedule for Affective Disorders and Schizophrenia for School-Age Children, Orvaschel et al., 1982)\n\n    o History of epileptic episodes\n\n    o Immunosuppressive treatment or known immunoinflammatory disease\n\n    →As a reminder : exclusion criteria C16-89\n  * 1\\) Probands with Autism Spectrum Disorder\n\n    o Severe intellectual disability (IQ\\\u003C35 or developmental age \\\u003C18 months)\n  * 2\\) Controls (neurotypical development)\n\n    o Identified intellectual disorder or cognitive developmental disorder\n    * Personal psychiatric history of schizophrenia, bipolar disorder, substance use disorders (except tobacco), recurrent depression (\\>2 episodes, lifetime), severe unstabilized anxiety disorder\n    * History of epilepsy episodes or severe neurological disease\n  * 3\\) Relatives of the TSA applicants or controls\n\n    * Medical condition (psychiatric or somatic) not compatible with inclusion","2 Years",{"count":134,"type":20},450,[57],"Autism spectrum disorder (ASD) is a neurodevelopmental disorder characterized by deficits in social interaction and verbal and non-verbal communication (DSM-5, 2013), affecting approximately 2% of the general population. In 5 to 40% of cases, genetic factors are identified as the cause of these disorders, with prevalence depending on the technique used (exomes and\u002For SNP arrays) and the associated intellectual deficit. In the majority of cases, the etiology remains unknown. Studies of microdeletions\u002Fmicroduplications (copy number variants) or Whole Exome Sequencing and Whole Genome Sequencing (Single Nucleotide Variants) show the involvement of numerous genes in the predisposition to autism. ASD remains a genetically heterogeneous disorder, as more than 250 genes have been associated with ASD to date.\n\nThe main objective of the project is to continue identifying genetic factors, and also to understand the biological mechanisms involved in the emergence of autistic symptoms.\n\nIdentifying biological pathways is an essential step in developing new therapeutic strategies. In addition, one of the major challenges of this study is to better understand the phenotype\u002Fgenotype relationships in ASD. This requires in-depth knowledge of the phenotypic characteristics of participants with ASD and their families, as well as neurotypical populations. This study combines the scientific expertise of researchers specializing in molecular biology, phenotypic exploration (clinical, cognitive, MRI, EEG, biochemistry, immunology), and the use of pre-therapeutic cellular models (iPSCs, neural precursors, organoids).\n\nThe objective of this work is the identification of numerous genes associated with ASD and involved in synaptic formation and regulation: NLGN3-4, SHANK1 and SHANK3, CNTN-6, and CNTNAP4. This work was combined with in-depth phenotypic explorations of ASD participants and their relatives. It has made it possible to clarify the neuroanatomical characteristics of participants with ASD and their genetic substrate, as well as the underlying cognitive processes.\n\nAll of this work opens up new prospects for identifying new therapeutic targets using preclinical cell models (IPSCs Induced pluripotent stem cells, neural progenitors, organoids) developed in particular by I-Stem and Human Technopole.",[138,139],"Autism Disorder","ASD",[141,142,143,144,145],"autism","genes","phenotype","complex heritability","Induced pluripotent stem cells",{"date":118,"type":34},{"date":148,"type":20},"2026-08-01",{"date":150,"type":20},"2041-08-01",{"name":40,"class":41},{"id":153,"slug":154,"hasResults":12,"nctId":155,"briefTitle":156,"officialTitle":156,"acronym":157,"eligibilityCriteria":158,"healthyVolunteers":50,"sex":17,"minAge":51,"maxAge":159,"enrollmentInfo":160,"targetDuration":4,"studyType":55,"phases":162,"briefSummary":163,"conditions":164,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":116,"lastUpdatePostDateStruct":171,"startDateStruct":172,"completionDateStruct":174,"leadSponsor":176,"locationsCount":42},"100598420","study-of-the-correlation-between-cortical-excitability-and-cytoarchitectonics-of-prefrontal-cortex-in-healthy-adult-participants-using-transcranial-magnetic-stimulation-coupled-to-eeg-and-high-field-mri-100598420","NCT07071259","Study of the Correlation Between Cortical Excitability and Cytoarchitectonics of Prefrontal Cortex in Healthy Adult Participants, Using Transcranial Magnetic Stimulation Coupled to EEG and High-field MRI","FrontalProbe","Inclusion Criteria:\n\n* People aged 18 to 35\n* People affiliated with a social security scheme or beneficiary of such a scheme\n* People who have signed the informed consent\n* Right-handed people\n* People with a body mass index between 18 and 26\n* People able to abstain from alcohol for 24 hours prior to the experiment\n* People able to remain perfectly still for 15 minutes straight, and able to have reduced mobility for 3 hours\n* People able to of not using narcotics (marijuana, cocaine, ecstasy, MDMA, ketamine, etc.) during the 15 days preceeding the experiment.\n* Conducting a pregnancy test before inclusion for women of childbearing age and when the research is conducted over a long period, at a frequency adapted to the gaze of the research acts\n* Effective contraception for women of childbearing potential\n\nExclusion Criteria:\n\n* Pregnant, parturient, or breastfeeding\n* Protected adults\n* Minors\n* People staying in a healthcare or social institution\n* People in an emergency situation\n* People deprived of their liberty\n* People with the usual contraindications to MRI\n\n  * Ferromagnetic surgical clips, ocular implants, metallic foreign bodies intraocularly or in the nervous system, implants or metallic objects susceptible to concentrate the radio frequency field, cochlear implants, brain stimulator or cardiac pacemaker, presence of a craniotomy scar, agitation\n  * Claustrophobia\n  * Large, black tattoo close to the orofacial area\n* People not wishing to be informed of abnormalities discovered at the MRI\n* People with a history of epilepsy or suffering from epilepsy\n* Individuals whose parents, children, siblings, or parents have a history of epilepsy\n* People with known neurological and\u002For psychiatric disorders with past and\u002For current medical treatment, or drug addiction\n* Staff with a hierarchical link to the investigators","35 Years",{"count":161,"type":20},34,[57],"Repeated transcranial magnetic stimulation (rTMS) is mainly used to treat mood disorders by addressing differences in brain function, particularly in the dorsolateral prefrontal cortex (DLPFC), which affects emotions and executive functions. The therapy aims to enhance the left DLPFC or suppress the right. It has been approved for severe major depression in several countries (Canada and Israel since 2002, USA since 2008) and is in the process of being validated in Europe but is not yet reimbursed in France. due to variable results from one study to another and lack of standardization issues.\n\nIn a previous study, by recording electroencephalographic (EEG) rhythms before and after rTMS treatment of the DLPFC, the investigators showed on a small cohort of patients (n=17) with major or bipolar depression, that the responder patients showed higher EEG theta rhythms in the DLPFC but also and especially in parietal regions. This suggests that the DLPFC is part of the fronto-parietal central executive network (CEN), which is important for working memory and cognitive control. The CEN is not well connected in severe resistant depression, possibly leading to negative emotional bias. The rTMS cure of DLPFC can be interpreted as improving depressive symptoms through the normalization of the CEN by increasing DLPFC excitability and its downward connectivity. However experimental and clinical evidence for this mechanism, among others, is still to be demonstrated, and remission rates of rTMS from DLPFC in drug-resistant depression are still low (20-40%).\n\nTo improve these response rates to rTMS in DLPFC, it is essential to continue research aimed at improving clinical practices through a better knowledge of the functional neuroanatomy and mechanisms of action of rTMS. This will require the definition of biomarkers allowing in particular to better target the DLPFC, this structure beeing indeed relatively poorly defined on the neuroanatomical level (large portion of the medial frontal gyrus). To this end, the investigators have set up a collaborative research program with Dr. Corey Keller, psychiatrist at Stanford University USA, which was jointly funded in 2022 by the Agence Nationale pour la Recherche (ANR) and the National Institute of Health (NIH) - FrontalProbe project \"Probing the dorsolateral prefrontal cortex and central executive network for improving neuromodulation in depression\". The ultimate aim of this project is to develop and test different strategies for targeting the DLPFC in the rTMS treatment of pharmaco-resistant depressive patients, following the fundamental neuroanatomical and pathophysiological hypothesis that patients will respond better to therapy if their CEN network is better modulated. This clinical trial will take place in Stanford, USA, in the years 2025-2026. Previously, the investigators are working on the development of methodological strategies aimed at preferentially activating, in a personalized way, the part of the DLPFC that projects onto the PPC. This is the subject of the present protocol, which aims to identify this subpart of the DLPFC to be targeted as a priority for modulating the CEN, through neuroanatomical measurements with high-field MRI and cortical excitability by TMS-EEG in healthy subjects. To this end, the investigators will use a small cohort of healthy subjects who will have one multimodal MRI acquisition session of at 7T and one TMS-EEG session. The 7T MRI data, acquired at the Centre de Résonance Magnétique en Biologie et Médecine (CRMBM), will be used to obtain anatomical markers of the DLPFC. TMS-EEG data, acquired at the Institut de Neurosciences de Systèmes (INS), will be used for cortical excitability measurements of the DLPFC and its projection sites, notably the PPC. At this stage, no data exchange is planned with our American partners.\n\nFirstly, the processing of MRI data will include segmentation of gray and white matter, reconstruction of the cortical surface and estimation of the different cortical layers, mainly by monitoring variations in the T1 parameter along the cortical mantle. Other MRI parameters will also be acquired to maximize the specificity of the segmentation of the DLPFC into sub-regions, firstly by identifying the part of the DLPFC that connects preferentially to the PPC using the reconstruction of fiber bundles from diffusion MRI and functional resting MRI. Secondly, during TMS-EEG acquisitions, participants will be stimulated in 3 sub-regions of the DLPFC. For each target, the analyses of the EEG data will focus on quantifying connectivity with the PPC as well as their spectral signature, which is possibly an indirect reflection of the neuronal composition of the stimulated regions.\n\nCorrelation of 7T MRI and TMS-EEG data will help set optimal DLPFC targeting criteria for PPC activation. The aim is to create an MRI-based targeting procedure for clinical practice. In this sense, TMS-EEG will serve as validation of MRI markers.",[165,166,167,168,169,170],"Healthy Participants","Magnetic Stimulation","MRI","EEG","Dorsolateral Prefrontal Cortex","rTMS Stimulation",{"date":118,"type":34},{"date":173,"type":20},"2026-07-15",{"date":175,"type":20},"2028-04",{"name":40,"class":41},{"id":178,"slug":179,"hasResults":12,"nctId":180,"briefTitle":181,"officialTitle":182,"acronym":183,"eligibilityCriteria":184,"healthyVolunteers":12,"sex":17,"minAge":51,"maxAge":185,"enrollmentInfo":186,"targetDuration":4,"studyType":55,"phases":188,"briefSummary":189,"conditions":190,"keywords":4,"overallStatus":192,"whyStopped":4,"lastUpdateSubmitDate":116,"lastUpdatePostDateStruct":193,"startDateStruct":194,"completionDateStruct":196,"leadSponsor":198,"locationsCount":42},"100589178","impact-of-rtms-on-bci-control-in-upper-limb-motor-rehabilitation-of-patients-with-chronic-stroke-100589178","NCT06951035","Impact of rTMS on BCI Control in Upper Limb Motor Rehabilitation of Patients With Chronic Stroke","ETUDE DE L'AMELIORATION DU CONTROLE DES INTERFACES CERVEAU-MACHINE PAR LA CONNECTIVITE FONCTIONNELLE ET LA STIMULATION MAGNETIQUE TRANSCRANIENNE REPETEE DANS LA REEDUCATION MOTRICE DU MEMBRE SUPERIEUR APRES UN ACCIDENT VASCULAIRE CHRONIQUE","BCINET","Inclusion Criteria:\n\n* Single Stroke older than 6 months\n* Distal motor deficit of the upper limb (UE-FMA score \\\u003C 53) with visible extension of the fingers (Medical Research Council (mRC) score ≥ 2)\n* Right-handed\n* Between 18 and 85 years of age\n* Having given their written consent\n\nExclusion Criteria:\n\n* Patient under tutorship or guardianship, under safeguard of justice, deprived of liberty, pregnant or breast feeding women\n* Life-threatening pathologies or compromising follow-up during the study period\n* Trouble of understanding : score below 12\u002F15 in the Boston Diagnostic Aphasia Examination (BDAE) order execution test\n* Fixed spasticity of finger or carpal flexors (mAS score = 4) or botulinum toxin injection less than 12 weeks old in the forearm or hand\n* History of degenarative neurological pathology or craniectomy\n* Deficient upper limb skin lesion preventing use of mucle stimulation\n* Skin lesion of the scalp preventing EEG placement\n* Participation in biomedical therapeutic research that may affect the recovery of the deficient hand during the study\n* Patient who has previously participated in a therapeutic study rTMS (excluding single shock) or a BCI\n* Patient who does not wish to be informed of a brain abnormality discovered accidentally on MRI","85 Years",{"count":187,"type":20},50,[57],"Cerebrovascular accidents (strokes) are a major public health issue. Stroke is the 3rd leading cause of death and the leading cause of disability and loss of autonomy. In France, there are currently 130,000 new cases per year, and the aging of the population will lead to an increase in this number over the next few years. Among post-stroke impairments, motor deficit of the upper limb is the most common disability, affecting 73-88% of first-time stroke patients and 55-75% of chronic patients. Associated deficits can complicate rehabilitation management and affect recovery. The clinical profile of patients with motor deficits is therefore varied and complex, requiring an individualized approach. At present, only physiotherapy is recommended, with modest results.\n\nRepeated transcranial magnetic stimulation is a therapy that can improve motor recovery, but currently has a low level of evidence according to the HAS (French Hight Health Authority), notably because of variability in efficacy due to heterogeneity in the clinical profile of patients. Nevertheless, it is still recommended for the recovery of cognitive functions, but also for resistant depression, and could be used to stimulate motor imagery (MI). MI training also has the advantage of stimulating the motor network. Difficult to achieve for a number of patients, the use of rTMS could facilitate this cognitive task and, in particular, provide better access to brain-computer interfaces (BCI). Indeed, among the innovative rehabilitation therapies, BCIs have emerged as the most promising. By translating brain activity during a cognitive task into a command such as electrical muscle stimulation, BCIs would restore the damaged motor network and induce motor recovery. The main obstacle to their widespread use in clinical practice is their lack of reliability, as almost 30% of patients are unable to control them correctly, either because of difficulty in performing the MI task, or because of difficulty in identifying a universal brain signature.\n\nThe BCINET project aims to improve the reliability of BCIs in two ways: by improving detection of the motor imagination task using new brain signatures, and through cognitive facilitation using rTMS.\n\n1. \\- Using the dynamic communication of different brain areas during the MI task (or functional connectivity), we can identify patient-specific signatures. Studies of functional connectivity in healthy subjects performing an MI task without associated BCI have shown the interest of certain measures such as node degree or clustering coefficient. To find out whether functional connectivity parameters can be used in BCI algorithms, we will evaluate their effectiveness on an initial group of 5 patients to define their performance in discriminating the MI task and to determine their evolution over time in the absence of brain stimulation in stroke patients. Their initial study will also enable us to identify their evolution when TMS stimulation is applied.\n2. \\- Cerebral magnetic stimulation could facilitate the MI task and enable better BCI rehabilitation for a number of patients. Two studies using either an inhibitory or excitatory stimulation protocol showed an improvement in spectral power signal and better discrimination of the MI task. However, the results were acquired using a single pre- and post-therapy measurement, and did not take into account behavioral variability in the use of BCIs or variability in TMS response according to patient profile. Therefore, in order to identify whether rTMS would improve BCI control, we would perform 9 Single-Case Experimental Design (SCED) studies in multiple baselines on a group of 5 patients according to 3 clinical profiles and 3 rTMS stimulation strategies. SCEDs are suitable experimental models for heterogeneous populations, particularly when the intervention presents some inter-individual variability in efficacy. They have the advantage of being able to demonstrate, on an individual scale, the effectiveness of the intervention on a small group of patients. Replication of the SCED allows us to increase the external validity of the intervention on sub-groups of patients (clinical severity, presence of associated hemineglect) and to study modifications in the interventional strategy (stimulation frequency, stimulation site).",[191],"Chonic Stroke Patients With Motor Impairment of Upper Limb","RECRUITING",{"date":118,"type":34},{"date":195,"type":34},"2025-04-25",{"date":197,"type":20},"2029-04",{"name":40,"class":41},{"id":200,"slug":201,"hasResults":12,"nctId":202,"briefTitle":203,"officialTitle":204,"acronym":205,"eligibilityCriteria":206,"healthyVolunteers":12,"sex":17,"minAge":51,"maxAge":207,"enrollmentInfo":208,"targetDuration":4,"studyType":55,"phases":209,"briefSummary":210,"conditions":211,"keywords":213,"overallStatus":192,"whyStopped":4,"lastUpdateSubmitDate":116,"lastUpdatePostDateStruct":220,"startDateStruct":221,"completionDateStruct":223,"leadSponsor":225,"locationsCount":42},"100570023","neural-correlates-of-movement-disorders-associated-with-prrt2-related-paroxysmal-kinesigenic-dyskinesia---an-ancillary-study-of-amedyst-research-100570023","NCT06701851","Neural Correlates of Movement Disorders Associated With PRRT2 Related Paroxysmal Kinesigenic Dyskinesia - an Ancillary Study of AMEDYST Research","Corrélats Neuronaux Des Accès de Mouvements Anormaux Paroxystiques Liées Aux Dyskinésies Paroxystiques kinésigéniques Secondaires à Une Mutation du Gene PRRT2 - Recherche Ancillaire de L'étude AMEDYST \" Dont Vous êtes l'Investigateur Principal","TRIGGER","Inclusion Criteria:\n\nMale or female Individuals with dystonic disease carrying a PRRT2 mutation and demonstrating the ability to control paroxysmal dyskinesia episodes.\n\nAffiliated with a health insurance system or a beneficiary of such a system. Individuals aged 18 to 75 years. Signature of informed consent\n\nExclusion Criteria:\n\nIndividuals under guardianship. Individuals not residing in France. Individuals unable to comply with protocol constraints (compliance with visit schedules and ability to perform required tasks).\n\nIndividuals undergoing an exclusion period for another research study. Contraindications to MRI","75 Years",{"count":42,"type":20},[57],"The main objective of this study is to investigate in real-time the neuronal correlates of paroxysmal dyskinesia episodes related to the PRRT2 mutation within this subgroup of patients (who can control paroxysmal dyskinesia episodes), and more specifically, the pathological role of the reciprocal influence between the striatum and the cerebellum in paroxysmal dyskinesia episodes.",[212],"Paroxysmal Dyskinesia",[214,215,216,217,218,219,168],"dyskinesia","voluntary movements","cerebellum","basal ganglia","cortex","fMRI",{"date":118,"type":34},{"date":222,"type":34},"2025-01-21",{"date":224,"type":20},"2029-10",{"name":40,"class":41},{"id":227,"slug":228,"hasResults":12,"nctId":229,"briefTitle":230,"officialTitle":230,"acronym":231,"eligibilityCriteria":232,"healthyVolunteers":50,"sex":17,"minAge":233,"maxAge":4,"enrollmentInfo":234,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":236,"conditions":237,"keywords":239,"overallStatus":192,"whyStopped":4,"lastUpdateSubmitDate":245,"lastUpdatePostDateStruct":246,"startDateStruct":248,"completionDateStruct":250,"leadSponsor":252,"locationsCount":253},"100449999","beat1d-benign-autoimmunity-and-type-1-diabetes-100449999","NCT05139784","BeAT1D: Benign Autoimmunity and Type 1 Diabetes","BeAT1D","Inclusion Criteria:\n\n1. Type 1 diabetes: type 1 diabetes, as defined by hyperglycemia and long-term insulin therapy started within 6 months from clinical onset; and\u002For the presence of at least one anti-islet auto-antibody.\n2. Other forms of diabetes or autoimmune endocrinopathy: other forms of diabetes (e.g. type 2, ketosis-prone, familial, secondary, immunotherapy-induced diabetes); and\u002For other autoimmune endocrinopathies, isolated or multiple.\n3. No diabetes: absence of diabetes or impaired glucose tolerance; absence of tumor, infectious or immune pathologies, or other conditions related to autoimmune or metabolic alterations that may bias the variables under study.\n4. Lymphadenectomy planned in the frame of an abdominal surgery: pancreatic lymphadenectomy planned at the occasion of an abdominal surgery for the treatment of an underlying condition.\n\nExclusion Criteria:\n\nFor all participants: ongoing pregnancy; known HIV\u002FHCV infection; absence of social security coverage; placement under judicial protection; absence of signature of the informed study consent.","1 Year",{"count":235,"type":20},1160,"National multi-center non-interventional case-control cohort study with collection of biological samples to characterize the autoimmune T and B lymphocytes involved in the development of type 1 diabetes.",[238],"Type 1 Diabetes",[240,241,242,243,244],"Type 1 diabetes","Autoimmunity","Lymphocytes","Beta cells","Biomarkers","2026-05-20",{"date":247,"type":34},"2026-05-22",{"date":249,"type":34},"2022-10-24",{"date":251,"type":20},"2030-04",{"name":40,"class":41},17,{"id":255,"slug":256,"hasResults":12,"nctId":257,"briefTitle":258,"officialTitle":259,"acronym":260,"eligibilityCriteria":261,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":262,"enrollmentInfo":263,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":265,"conditions":266,"keywords":271,"overallStatus":192,"whyStopped":4,"lastUpdateSubmitDate":277,"lastUpdatePostDateStruct":278,"startDateStruct":280,"completionDateStruct":282,"leadSponsor":284,"locationsCount":285},"100570778","prenatal-maternal-mental-health-and-neurodevelopment-in-congenital-heart-disease-100570778","NCT06711666","Prenatal Maternal Mental Health and Neurodevelopment in Congenital Heart Disease","Prenatal Maternal Mental Health and Neurodevelopment in Children With an Antenatal Diagnosis of Congenital Heart Disease: The Neuro-Moms CHD Study","Neuro-Moms","Inclusion Criteria for the mother of a child diagnosed with CHD:\n\n1. Age at least 18 years old\n2. Expecting women\n3. Having received a diagnosis of foetal critical cyanotic CHD (i.e., CHD physiology that can compromise blood oxygenation after birth). This type of CHDs corresponds to the highest level of neurological risk as reported by the American Heart Association guidelines(1).\n4. Pregnancy of at least 28 weeks of gestation (third trimester) and up to the 38 weeks of gestation at the time of enrolment and prenatal visit for the study.\n5. Medical maternal and paediatric cardiology follow-up in one of the investigating hospitals (Montpellier, Necker Children's Hospital in Paris and Bordeaux).\n6. A delay of a minimum of 4 weeks between the initial diagnosis of foetal congenital heart disease.\n7. Social security affiliation in France.\n\nInclusion criteria for the father or co-parent:\n\n1. Co-parent of an expecting woman participating in the study\n2. Age at least 18 years old\n3. Social security affiliation in France.\n\nInclusion criteria for the child diagnosed with congenital heart disease:\n\n1. Child with a prenatal diagnosis of isolated complex congenital heart disease, born to a mother already participating in the study\n2. Written consent from both parents\n3. Social security affiliation in France.\n\nNon-inclusion Criteria for mothers:\n\n1. Patient refusal to participate\n2. Participants (i.e., expecting women) who express a wish for medical termination of pregnancy\n3. Diagnosis of a complex CHD associated with another foetal comorbidity with a clinically recognized impact on neurodevelopment (e.g., genetic syndromes such as trisomies, poly-malformation syndromes).\n4. Participants who are not able to understand the instructions and\u002For complete the self-reports\n5. Expecting women who currently have a major psychiatric condition (e.g., untreated major depression, severe anxiety disorders, psychotic disorders) with or without treatment, at the time of the cardiology consultation or at the time of the first psychological evaluation. Patients who will be excluded due to these conditions will be referred for perinatal psychiatric consultation.\n6. Persons under legal or judicial guardianship.\n\nNon-inclusion Criteria for fathers or co-parents:\n\n1. Patient refusal to participate\n2. Participants with a severe psychiatric disorder (severe depression, psychotic disorders) with or without treatment\n3. Persons under legal or judicial guardianship.\n\nExclusion Criteria for the mother of a child diagnosed with CHD:\n\n1\\. The child has not undergone surgery within 60 days of birth.\n\nExclusion Criteria for children with CHD:\n\n1\\. Genetic anomalies, brain malformations that may render difficult the neurodevelopmental assessment.","50 Years",{"count":264,"type":20},174,"Congenital heart disease (CHD) is the leading cause of congenital malformations, representing 1% of live births. Progress in surgical care have led to the dramatic increase in the population of children and adults living with heart disease. As survival is no longer a concern, long-term outcomes have become the major public health issue. Prenatal diagnosis of CHD requiring open-heart surgery can be a traumatic event for expecting mothers and fathers. In the general population, maternal mental health distress is associated with fetal disturbances in the hypothalamic-adrenal-pituitary system axis, restricted intrauterine growth and adverse outcomes in the offspring. It is unknown whether prenatal maternal psychological distress have an impact on neurodevelopmental outcomes in CHD. Our national study seeks to (1) characterize the impact of prenatal maternal psychological distress on neurodevelopmental outcomes at age 1 for children with CHD who undergo neonatal open-heart surgery; (2) investigate the sociodemographic and medical determinants associated with prenatal maternal mental health of women carrying a foetus diagnosed with complex CHD; (3) explore the mediating role of prenatal risk factors (i.e., sociodemographic, medical and maternal coping mechanisms) in the association of prenatal maternal mental health (i.e., distress, anxiety and depression) and neurodevelopment in children with CHD; and (4) explore the impact of paternal or the co-parent's mental health impact on neurodevelopmental outcomes at age 1 in children with CHD. This study is a non-interventional, prospective, and longitudinal study of prenatal maternal mental health and subsequent child's neurodevelopmental and behavioural outcomes. It includes a follow-up period from the 3rd trimester of pregnancy until the child's first year of life. It will include children with a prenatally diagnosed heart defect requiring open-heart surgery within the first weeks of life. Understanding and preventing the neurodevelopmental sequelae of heart disease diagnosed in-utero is a public health priority.",[267,268,269,270],"Congenital Heart Disease","Cyanotic Congenital Heart Disease","d-Transposition of the Great Arteries","Hypoplastic Left Heart Syndrome",[272,273,274,275,276],"psychological stress","Maternal prenatal mental health","Neurodevelopment","Cyanotic congenital heart disease","Prenatal diagnosis","2026-05-11",{"date":279,"type":34},"2026-05-12",{"date":281,"type":34},"2025-06-27",{"date":283,"type":20},"2028-01",{"name":40,"class":41},5,{"id":287,"slug":288,"hasResults":12,"nctId":289,"briefTitle":290,"officialTitle":291,"acronym":292,"eligibilityCriteria":293,"healthyVolunteers":50,"sex":17,"minAge":51,"maxAge":294,"enrollmentInfo":295,"targetDuration":4,"studyType":55,"phases":297,"briefSummary":299,"conditions":300,"keywords":302,"overallStatus":192,"whyStopped":4,"lastUpdateSubmitDate":305,"lastUpdatePostDateStruct":306,"startDateStruct":308,"completionDateStruct":310,"leadSponsor":312,"locationsCount":42},"100587582","phase-2-dopaminergic-disruption-induced-by-traumatic-coma-dopaminergic-pathways-abnormalities-and-biomarkers-of-recovery-using-mri-and-18f-lbt-999-pet-100587582","NCT06930261","Dopaminergic Disruption Induced by Traumatic Coma: Dopaminergic Pathways Abnormalities and Biomarkers of Recovery Using MRI and 18F-LBT-999 PET","Dopaminergic Disruption Induced by Traumatic Coma: Multimodal Neuroimaging Approaches to Characterize Dopaminergic Pathways Using 18F-LBT-999 PET","ComaDopa","Inclusion Criteria:\n\nFor All Participants:\n\n* Aged 18-65 years.\n* Affiliated with or beneficiary of a social security system.\n* Signed informed consent provided by the participant or a trusted representative (for patients).\n\nFor all TBI Participant\n\n* Hospitalized for a non-penetrating traumatic brain injury (TBI) occurring within the last 30 days, with traumatic coma (Glasgow Coma Scale (GCS) \\\u003C 10 and motor score (M) \\\u003C 6) at hospital admission.\n* Sedative treatments discontinued for more than 48 hours.\n* Clinically stable (no hemodynamic, respiratory, or metabolic instability requiring specific interventions that contraindicate medical transfer to the imaging center).\n\nFor the TBI-COMA Group:\n\n\\- Severe TBI characterized by prolonged coma, defined as an initial GCS \\\u003C 10 with M \\\u003C 6, and no recovery of consciousness at inclusion (GCS \\\u003C 10 with M \\\u003C 6).\n\nFor the TBI-REC Group:\n\n* Severe TBI characterized by prolonged coma, defined as an initial GCS \\\u003C 10 with M \\\u003C 6, with recovery of consciousness evidenced by simple command-following (GCS ≥ 10 with M = 6) at inclusion.\n* For Healthy Controls:\n\nMatched by age (± 2 years) and sex to patients in the TBI-COMA group.\n\nExclusion Criteria:\n\nFor All Participants:\n\n* Pregnant or breastfeeding women\n* Contraindications to MRI\n* Known allergy to the PET radiotracer or its excipients.\n* History of conditions affecting the dopaminergic system\n* Individuals under legal protection measures\n* Current treatment with dopaminergic agonists or antagonists.\n\nFor Patients Only:\n\n* Coma due to causes other than TBI.\n* Decompressive craniectomy resulting in anatomical alterations incompatible with standardized image analysis (e.g., midline shift \\> 2 cm).\n\nFor Healthy Controls Only:\n\n* Women of childbearing potential without effective contraception.\n* Women unwilling to maintain effective contraception during the 30-day study period.","65 Years",{"count":296,"type":20},55,[298],"PHASE2","The neural correlates of consciousness have been studied at the macroscopic level. However, the neurochemical basis of these processes remains poorly understood. The mesocircuit theory challenges the cortico-centric view of consciousness. It highlights the role of subcortical regulation by dopaminergic circuits, including the ventral tegmental area and striatal loops. Experimental data show the importance of dopamine in consciousness recovery. Animal TBI studies link dopamine deficits to loss of consciousness and recovery. In humans, imaging studies show disrupted dopaminergic networks in chronic consciousness disorders. Yet, early-phase dopaminergic disruptions in acute coma remain underexplored.\n\nMolecular imaging with PET or SPECT offers insights into dopamine system disturbances. The novel radiotracer 18F-LBT-999 enables detailed imaging of dopaminergic circuits, providing better spatial resolution and quantification than SPECT.\n\nThis proof of concept study aims to explore acute subcortical dopaminergic loop disruptions. It will combine 18F-LBT-999 PET with structural and functional MRI in post-traumatic coma.\n\nMethods : Patients with severe traumatic brain injury (TBI) admitted to the intensive care unit state will be evaluated within 30 days post-injury. Participants will undergo clinical assessment after sedation clearance and will be categorized into three groups: (1) TBI-COMA (severe TBI with persistent coma), (2) TBI-REC (severe TBI with recovery of command-following), and (3) healthy controls. All participants will undergo clinical evaluations, anatomical and functional MRI, and molecular imaging: 18F-LBT-999-PET. Neurological outcome (CRS-r scale), Disability rating scale (DRS), Quality of life (QUOLIBRI) and axtrapyramidal symptoms (MDS-UPDRS) will be assessed at 3 month.\n\nPrimary Hypothesis: Acute post-traumatic severe TBI patients with persistent coma (TBI-COMA) show reduced presynaptic dopamine receptor levels in the striatum, compared to healthy controls.\n\nSecondary Hypotheses:\n\n* Dopaminergic disruptions correlate with the severity of consciousness impairment, differentiating TBI-COMA and TBI-REC groups.\n* Structural damage in the striatum and nigrostriatal tract, identified via MRI, aligns with dopaminergic abnormalities.\n* Multimodal imaging findings during the acute phase can predict long-term neurological and quality-of-life outcomes.\n* Characterizing structural, functional, and metabolic variations in dopaminergic networks may guide personalized pharmacological treatments.",[301],"Coma, Traumatic",[303,304],"moderate traumatic brain injury","severe traumatic brain injury","2026-05-04",{"date":307,"type":34},"2026-05-08",{"date":309,"type":34},"2025-01-14",{"date":311,"type":20},"2028-09",{"name":40,"class":41},{"id":314,"slug":315,"hasResults":12,"nctId":316,"briefTitle":317,"officialTitle":318,"acronym":319,"eligibilityCriteria":320,"healthyVolunteers":50,"sex":321,"minAge":51,"maxAge":207,"enrollmentInfo":322,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":324,"conditions":325,"keywords":327,"overallStatus":192,"whyStopped":4,"lastUpdateSubmitDate":333,"lastUpdatePostDateStruct":334,"startDateStruct":335,"completionDateStruct":337,"leadSponsor":339,"locationsCount":340},"100575555","chlordecone-exposure-and-prostate-cancer-in-the-french-region-of-martiniique-100575555","NCT06773806","CHLORDECONE EXPOSURE AND PROSTATE CANCER IN THE FRENCH REGION OF MARTINIIQUE","LIEN ENTRE EXPOSITION A LA CHLORDECONE ET CANCER DE LA PROSTATE EN MARTINIQUE","CHLOECAPA","INCLUSION CRITERIA\n\nTo take part in this research, participants must meet the following criteria:\n\nPatients\u002Fcases :\n\n* All men newly diagnosed with Prostate Cancer in Martinique during a three-year given period in all public and private services caring for patients with Prostate Cancer, identified via multidisciplinary consultation meetings.\n* Male adults under 75 years of age\n* Resident in Martinique for at least 6 months\n* Histologically confirmed (inclusion possible as soon as the result is known by the urologist)\n* Affiliated to a social security scheme or equivalent\n* Have signed a free and informed consent form\n\nBiopsy-negative\" controls (Group 1 controls):\n\n* All men with a negative prostate biopsy following elevated Prostate Specific Antigen (PSA) assay (\\> 2.5 ng\u002Fml) within a 3-year period in all public and private services in Martinique identified via urologists or pathologists.\n* Male adults under 75 years of age\n* Resident in Martinique for at least 6 months\n* Frequency matched on age (+\u002F- 5 years) to patients\n* Affiliated to a social security scheme or equivalent\n* Signed free and informed consent\n\nPSA-negative\" controls (Group 2 controls):\n\n* All men with a PSA ⩽ 2.5 ng\u002Fml within a 3-year period and less than 3 months identified via a survey institute\n* Male adults under 75 years of age\n* Resident in Martinique for at least 6 months\n* Frequency matched on age (+\u002F- 5 years) against patients\n* Frequency matched on socio-professional category against men of the same age in Martinique (INSEE data)\n\nNON INCLUSION CRITERIA\n\nTo take part in this research, participants must not meet the following criteria:\n\n* Be subject to a legal protection measure (safeguard of justice, curatorship or guardianship).\n* Inability to consent because does not speak French or Creole.","MALE",{"count":323,"type":20},3600,"Prostate cancer is the most common male cancer in industrialized countries, including France, with over 60,000 new cases each year, and represents the third leading cause of cancer-related death in men.\n\nThe only known risk factors are age, ethnic origin and family history of prostate cancer. Indeed, there are considerable ethnic disparities in prostate cancer risk, with an incidence rate 60% higher in African-American men than in European-American men (Evans 2008). Similarly, in the French West Indies, where over 90% of the population is of Afro-Caribbean origin, the incidence of prostate cancer is twice as high as in mainland France. In 2015, the annual incidence was 88.5 cases per 100,000 in mainland France (Defossez 2021), while it was 184.1 cases per 100,000 in Guadeloupe, over the period 2008-2013 (Desloumeaux 2017), and 161.1 cases per 100,000 in Martinique, over the period 2005-2014 (Joachim 2019). The incidence rates observed in the French West Indies are of the same order as those observed in Afro-Caribbean populations in the UK and African-American populations in the USA (Ben Schlomo 2008, Evans 2008).\n\nThe reasons for these ethnic disparities in incidence are still poorly understood, but the role of genetic factors has been suggested. Indeed, certain genetic polymorphisms have been associated with an increased individual risk of prostate cancer in men of sub-Saharan African origin (Conti 2021; Karunamuni 2021; Marlin 2021). In addition, certain environmental factors (in the broadest sense) such as obesity, chronic inflammation, diet and certain environmental pollutants, including persistent organic pollutants (POPs) such as certain organochlorine pesticides, are also strongly suspected.\n\nAmong the suspected organochlorine pesticides is chlordecone, an insecticide used in the French West Indies until 1993, strongly suspected of playing a role in the occurrence of prostate cancer, particularly in the West Indies. Indeed, the Kannari study (Dereumeaux and Saoudi 2018), supported by Santé publique France, assessed the exposure of the West Indian population (Martinique and Guadeloupe) in 2013-2014 to chlordecone and certain organochlorine compounds , measured by serum levels, and quantified the determinants of this impregnation. The results of the study show that 90% of the West Indian population is indeed exposed to chlordecone, and demonstrate that chlordecone is still present in the environment (water and soil) and in food products, despite the cessation of its use in the West Indies in 1993.\n\nTo date, only one epidemiological study has explored the link between chlordecone exposure and the occurrence of prostate cancer, the Karuprostate study, a case-control study carried out between 2004 and 2007 in Guadeloupe, including 623 prostate cancer cases and 671 controls (Multigner 2010). Chlordecone exposure was measured by serum levels with an initial detection limit of 0.25 μg\u002FL (Multigner 2010), then improved to 0.06 μg\u002FL (Emmeville 2015). The authors highlighted a significant association between chlordecone exposure and prostate cancer, with a positive dose-response relationship (OR=1.77; 95% CI, 1.21 to 2.58 for the highest tercile). This association was more specifically observed in subjects with a family history of prostate cancer and in men who had lived in a Western country, requiring further investigation. The Karuprostate study also showed that serum levels of dichlorodiphenyldichloroethylene (DDE), the main and most stable metabolite of DDT, were significantly associated with the occurrence of CaP (Emmeville 2015). These results underline the interest of assessing, along with chlordecone, co-exposure to other persistent organic or organochlorine pollutants.\n\nFurthermore, DDE exhibits anti-androgenic effects and has been shown to repress the production of Prostatic-Specific Antigen (PSA) (target gene of the androgen receptor) by human prostate cancer cell lines (Wong 2015). The supposed effect of other organochlorines such as chlordecone on androgen receptors and thus on PSA levels could thus have important repercussions in terms of prostate cancer diagnosis. Individual screening for prostate cancer is based on serum PSA levels, followed in cases of elevated PSA (\\> 3-4 ng\u002Fml) by multiparametric Magnetic Resonance Imaging (mpMRI). A recent study showed that performing pre-biopsy mpMRI, regardless of PSA level, could lead to more men being diagnosed with clinically significant prostate cancer (Eldred-Evans 2021).\n\nFinally, there is a lack of preclinical studies to investigate the distribution of chlordecone in blood and tissues, as well as the link between chlordecone and markers of prostate cancer aggressiveness.\n\nWe therefore propose a case-control study in the general population of Martinique. This study will enable us to understand the nature of the link between chlordecone and prostate cancer.",[326],"Prostate Cancer",[328,329,330,331,332],"Epidemiology","Case-control study","Prostate cancer","Chlordecone","Pesticides","2026-04-28",{"date":305,"type":34},{"date":336,"type":34},"2026-04-15",{"date":338,"type":20},"2031-04",{"name":40,"class":41},2,{"id":342,"slug":343,"hasResults":12,"nctId":344,"briefTitle":345,"officialTitle":345,"acronym":346,"eligibilityCriteria":347,"healthyVolunteers":12,"sex":17,"minAge":348,"maxAge":349,"enrollmentInfo":350,"targetDuration":4,"studyType":55,"phases":352,"briefSummary":353,"conditions":354,"keywords":359,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":364,"lastUpdatePostDateStruct":365,"startDateStruct":367,"completionDateStruct":368,"leadSponsor":370,"locationsCount":371},"100635877","effectiveness-of-a-visual-telerehabilitation-program-on-visual-perception-in-children-adolescents-and-young-adults-with-hemianopsia-consecutive-to-a-brain-tumour-100635877","NCT07558395","Effectiveness of a Visual Telerehabilitation Program on Visual Perception in Children, Adolescents and Young Adults With Hemianopsia Consecutive to a Brain Tumour","REVIIH-BT","Inclusion Criteria:\n\n* Male and Female\n* 10 - 40 years old\n* Diagnosed hemianopsia (\\>12 months)\n* History of diagnosis brain tumour\n* Being stable for the tumour for \\> 6 months (either on therapy or not)\n* Visual acuity ≤ 0.7 LogMAR\n* Ability to follow the visual and auditory stimuli and training instructions\n* Home WiFi access\n* Ability to attend all on site visits\n* Affiliation to the Social Security or beneficiary of such social protection\n\nExclusion Criteria:\n\n* Age\\\u003C 10 years old of \\> 40 years old\n* Ocular disease\n* Inability to perform during testing or training\n* 3 consecutive VRISE scores \\\u003C 25 at inclusion\n* History of vertigo\n* Prior vision rehabilitation interventions\n* Recreational or medicinal consumption of psychoactive drugs\n* Persons under court protection\n* Interpupillary distance \\\u003C 54mm","10 Years","40 Years",{"count":351,"type":20},120,[57],"Evaluate the efficiency of audiovisual stimulation in virtual reality for improving the visual perception of children, adolescents, and young adults with hemianopia resulting from pediatric brain tumors. These individuals can lose up to 50% of their visual field, significantly impacting their independence, mobility, and daily lives.",[355,356,357,358],"Hemianopsia","Virtual Reality","Visual Rehabilitation","Pediatric Brain Tumor",[360,361,362,363],"brain tumor","pediatric","visual rehabilitation","virtual reality","2026-04-23",{"date":366,"type":34},"2026-04-30",{"date":120,"type":20},{"date":369,"type":20},"2029-09",{"name":40,"class":41},8,{"id":373,"slug":374,"hasResults":12,"nctId":375,"briefTitle":376,"officialTitle":376,"acronym":377,"eligibilityCriteria":378,"healthyVolunteers":12,"sex":17,"minAge":51,"maxAge":4,"enrollmentInfo":379,"targetDuration":4,"studyType":55,"phases":381,"briefSummary":383,"conditions":384,"keywords":386,"overallStatus":192,"whyStopped":4,"lastUpdateSubmitDate":389,"lastUpdatePostDateStruct":390,"startDateStruct":392,"completionDateStruct":394,"leadSponsor":396,"locationsCount":340},"100550429","phase-3-the-role-of-peripheral-afferents-in-modulating-post-stroke-central-pain-100550429","NCT06446960","The Role of Peripheral Afferents in Modulating Post-stroke Central Pain","APEDOC","Inclusion Criteria:\n\n1. Patients aged 18 years and over with no maximum age (blocks are generally very well tolerated in the very elderly)\n2. Pain in the upper or lower limb distal enough to be completely covered by a peripheral nerve block\n3. Chronic pain for at least 6 months\n4. Ischaemic or haemorrhagic stroke for at least 6 months documented clinically and by appropriate imaging (MRI)\n5. Post-stroke central neuropathic pain defined as pain occurring in the aftermath of stroke meeting the criteria for probable or defined neuropathic pain according to the NeuPSIG algorithm and with a DN4 screening questionnaire score of at least 4 out of 10.\n6. Spontaneous pain intensity greater than or equal to 4 out of 10 on an 11-point numerical scale (EN) at inclusion and randomisation (i.e. just before each block)\n7. Patients affiliated to a social security scheme or beneficiaries of such a scheme\n8. Stable oral analgesic pharmacological treatment for at least 2 weeks prior to inclusion\n9. Acceptance and signing of the informed consent\n\nExclusion Criteria:\n\n1. Inability or unwillingness to sign an informed consent\n2. Person subject to a legal protection measure (safeguard of justice, curatorship, guardianship)\n3. Patients with ongoing psychiatric pathology (major depression, psychosis) or cognitive disorders that prevent a good understanding of the protocol and questionnaires\n4. Pain that is too widespread in one hemicycle or limb and cannot be adequately covered by blocks\n5. Ongoing drug or substance abuse\n6. Language (aphasia) or comprehension disorders, illiteracy\n7. Moderate to severe renal or hepatic impairment\n8. Contraindication to local anaesthetics for use in perineural blocks (infection or acute inflammation in the injection area, known allergy).\n9. Pregnancy or breastfeeding\n10. Known hypersensitivity to lidocaine, levobupivacaine, amide-linked local anaesthetics or to any of the excipients contained in the specialities used in the study.\n11. Patients with recurrent porphyria or severe hypotension contraindicating treatment with lidocaine and\u002For levobupivacaine\n12. Current treatment with antiarrhythmic drugs causing torsades de pointes (amiodarone, disopyramide, quinidinics, sotalol...) or with antiarrhythmic drugs with local anaesthetic activity (mexiletine or class III antiarrhythmic drugs) and cannot be discontinued.\n13. Too little pain at the time of the blocks (\\\u003C 4 out of 10)\n14. Need to modify analgesic pharmacological treatment at the beginning or during the study",{"count":380,"type":20},36,[382],"PHASE3","Central post-stroke pain (CPP) is extremely difficult to relieve and responds very poorly to analgesics targeting neuropathic pain, probably because the mechanisms underlying this pain remain poorly understood.\n\nStroke pain is traditionally considered to be of central origin and related to changes in the spinal cord and\u002For brain nociceptive systems. However, a recent study in a small cohort of patients has suggested that the peripheral nervous system (PNS) may have a role in the initiation and persistence of APD.\n\nThe main objective of this prospective randomised controlled bicentric study (Raymond Poincaré and Ambroise Paré) in double blind and parallel groups against placebo (3 arms) will be to evaluate the efficacy of two peripheral nerve blocks performed 14 days apart on spontaneous neuropathic pain after stroke. The active treatments used for the blocks will be either lidocaine 20 mg\u002Fml or levobupivacaine 1.25 mg\u002Fml or placebo (saline)",[385],"Stroke",[387,388],"Ischemic Stroke","Central Neuropathic Pain","2026-04-17",{"date":391,"type":34},"2026-04-22",{"date":393,"type":34},"2024-02-09",{"date":395,"type":20},"2026-09-08",{"name":40,"class":41},{"id":398,"slug":399,"hasResults":12,"nctId":400,"briefTitle":401,"officialTitle":402,"acronym":403,"eligibilityCriteria":404,"healthyVolunteers":12,"sex":17,"minAge":405,"maxAge":4,"enrollmentInfo":406,"targetDuration":4,"studyType":55,"phases":407,"briefSummary":408,"conditions":409,"keywords":4,"overallStatus":192,"whyStopped":4,"lastUpdateSubmitDate":336,"lastUpdatePostDateStruct":411,"startDateStruct":413,"completionDateStruct":415,"leadSponsor":417,"locationsCount":418},"100566817","molecular-basis-of-language-development-and-associated-disorders-100566817","NCT06660108","MOLECULAR BASIS OF LANGUAGE DEVELOPMENT AND ASSOCIATED DISORDERS","BASES MOLECULAIRES DU DEVELOPPEMENT DU LANGAGE ORAL ET DES TROUBLES SPECIFIQUES ASSOCIES","TSLO","Patients\n\nInclusion Criteria:\n\n* Eligible families included at least one child over five years old with a formal diagnosis of severe and isolated DLD according to Phase 2 CATALISE criteria . Patients have undergone age-appropriate speech, language and reading evaluations by a speech-language physician and cognitive evaluations by a neuropsychologist, as well as evaluation by a pediatric neurologist to identify co-occurring developmental disorders (ADHD, ASD…) and a medical geneticist for known genetic disorders and genetic testing recommendations. All children included received appropriate speech therapy for at least one year, with a progress report indicating the persistence of language difficulties.\n\nExclusion Criteria:\n\n* Cognitive impairment with non-verbal intellectual quotient (IQ) below 2 SD assessed with the Wechsler Preschool and Primary Scale of Intelligence (WPPSI), or the Wechsler Intelligence Scale for Children (WISC-IV or V) according to the age-appropriateness, ASD, moderate to severe hearing loss, orofacial structural abnormalities, known neurological or genetic disorders at the initial assessment. None of the patients met the diagnostic criteria for CAS according to the ASHA (American Speech-Language-Hearing Association, 2007. Childhood apraxia of speech www.asha.org\u002Fpolicy).","5 Years",{"count":187,"type":20},[57],"Developmental Language Disorder (DLD) refers to children who present with language difficulties that are not due to a known biomedical condition or associated with autism spectrum disorder (ASD) or intellectual disability. The prevalence of DLD is \\~7%-8% or 2% if severe forms are considered.\n\nHowever, the clinical heterogeneity of language disorders, the presence of co-morbidities and the inconsistent terminology used for many years have hindered research and clinical practice. Distinguishing sub-groups of children with language problems is crucial when tackling the underlying genetic causes of this disease. Recently, several studies using high-throughput sequencing have better define the genetic basis of CAS but such studies focusing on DLD are limited. The investigation of more homogeneous cohorts of individuals that clearly distinguish DLD cases, from ID and not including children with CAS should improve our understanding of the genetic basis of this disorder.\n\nIn this study, we aim to built and investigate a well-characterized cohort of DLD patients using pangenomic approaches to better define the molecular basis of this disorder. All individuals will be analyzed using chromosomal microarray analysis and whole genome sequencing. Multiple observations and preliminary results suggest strong links with the genetic basis of other neurodevelopmental disorders.\n\nThe goal is to identify CNV or SNV as causative allele or risk factor and already known to be involved in other neurodevelopmental disorders as well as potential new variants.",[410],"Developmental Language Disorder",{"date":412,"type":34},"2026-04-20",{"date":414,"type":34},"2025-03-25",{"date":416,"type":20},"2028-03-25",{"name":40,"class":41},3,{"id":420,"slug":421,"hasResults":12,"nctId":422,"briefTitle":423,"officialTitle":424,"acronym":425,"eligibilityCriteria":426,"healthyVolunteers":50,"sex":17,"minAge":51,"maxAge":427,"enrollmentInfo":428,"targetDuration":4,"studyType":55,"phases":430,"briefSummary":431,"conditions":432,"keywords":4,"overallStatus":192,"whyStopped":4,"lastUpdateSubmitDate":336,"lastUpdatePostDateStruct":434,"startDateStruct":435,"completionDateStruct":437,"leadSponsor":438,"locationsCount":42},"100422745","tms-based-assessment-of-mental-training-effects-on-motor-learning-in-healthy-participants-100422745","NCT04784832","TMS-based Assessment of Mental Training Effects on Motor Learning in Healthy Participants","Transcranial Magnetic Stimulation-based Assessment of Mental Training Effects on Motor Learning in Healthy Participants","IMAP-TMS","Inclusion Criteria:\n\n* Male or female between 18 and 60 years old\n* Having given written informed consent\n* Affiliated to a social security scheme\n\nExclusion Criteria:\n\n* History of psychiatric illness (declarative)\n* Person under guardianship, curatorship, safeguard of justice\n* Neurological problem that could bias the results of the study (declarative)\n* Personal or family history of epilepsy\n* Person deprived of liberty by judicial or administrative decision\n* Person hospitalized without consent and not subject to legal protection, and person admitted to a health or social institution for purposes other than that of the research\n* Person subject to an exclusion period for another research\n* Pregnant women or women of childbearing age not using known contraception\n* Breastfeeding women\n* Person on medication that could influence neurophysiological measures (neuroleptics, anxiolytics, antidepressants)\n* Person carrying :\n* pacemaker or other device that could interfere with the magnetic field\n* Implants (mechanical or electronic: cochlear implants, neural or cardiac pacemakers, infusion pumps, magnetic aneurysm clips, etc.)\n* Metallic foreign bodies in the eye or nervous system\n* Metallic objects (tattoos, piercings, etc.)","60 Years",{"count":429,"type":20},556,[57],"The general purpose of this research project is to analyze the specific role of motor imagery on motor learning, assessed through corticospinal excitability measurements and behavioral data collection. This project is based on four sequences. For Sequence 1, the main objective is to examine the effect of mental training on movement speed and accuracy in a manual motor sequence task, as well as the influence of sensory feedback in immediate post-test (i.e., execution of a similar, but not identical, manual motor sequence, other manual tasks) on performance in delayed post-test. The secondary objective will be to examine corticospinal changes (i.e., amplitude of motor evoked potentials) induced by mental training, by measuring the amplitude of motor evoked potentials before and after mental training. For Sequence 2, the main objective is to examine the impact of a motor disturbance induced by a robotic arm at different intervals during the motor imagery process. The secondary objective will be to examine the corticospinal changes (i.e. amplitude of evoked motor potentials) induced by mental training as a function of the applied perturbations, before and after perturbation. For Sequence 3, the main objective will be to examine the influence of neuroplasticity on the quality of mental training. More specifically, the investigators will study the links between brain plasticity and motor learning through mental training. The secondary objective will be to examine the corticospinal changes (i.e. amplitude of evoked motor potentials) induced by mental training at different levels of the neuromuscular system (cortical, cervicomedullar, peripheral) after a training period. For Sequence 4, the main objective will be to examine the effect of short-term arm-immobilization of on the retention of motor learning induced by mental training. The secondary objective will be to examine the corticospinal changes (i.e., amplitude of motor evoked potentials) induced by of short-term arm-immobilization, or by transcranial direct current stimulation (tDCS), on motor learning. The results of this fundamental research project will allow a better understanding of neurophysiological and behavioral mechanisms that underlie motor learning through motor imagery. The results will allow to efficiently consider inter-individual specificities and will thus open up to clinical research perspectives, towards the establishment of adapted motor rehabilitation protocols.",[433],"Motor Learning",{"date":412,"type":34},{"date":436,"type":34},"2024-04-08",{"date":197,"type":20},{"name":40,"class":41},{"id":440,"slug":441,"hasResults":12,"nctId":442,"briefTitle":443,"officialTitle":444,"acronym":445,"eligibilityCriteria":446,"healthyVolunteers":50,"sex":17,"minAge":51,"maxAge":4,"enrollmentInfo":447,"targetDuration":4,"studyType":55,"phases":449,"briefSummary":450,"conditions":451,"keywords":4,"overallStatus":192,"whyStopped":4,"lastUpdateSubmitDate":453,"lastUpdatePostDateStruct":454,"startDateStruct":456,"completionDateStruct":458,"leadSponsor":460,"locationsCount":340},"100562189","cerebello-motor-neuromodulation-after-stroke-cerstim-100562189","NCT06599931","Cerebello-motor Neuromodulation After Stroke. CERSTIM.","CEREBELLO-MOTOR NEUROMODULATION AFTER STROKE","CERSTIM","PATIENTS\n\nInclusion Criteria:\n\n* Male or female aged 18 years or older on the day of inclusion.\n* Affiliated with a social security system, Universal Health Coverage (CMU), or any equivalent scheme.\n* Ischemic stroke or intraparenchymal hematoma that occurred more than 6 months ago, with no upper time limit.\n* Motor deficit of the upper limb confirmed by the ARAT scale, with the ability to grip and press on a tablet.\n* stroke lesion not affecting the motor cortex in the hand knob area.\n\nExclusion Criteria:\n\n\\-- Pregnant and breastfeeding women\n\n* Total paralysis of the affected hand\n* Conditions that are life-threatening or could compromise follow-up during the study period\n* Contraindications to MRI and tACS (ferromagnetic surgical clips, ocular implants, intraocular or nervous system metallic foreign bodies, implants or metallic objects likely to concentrate the radiofrequency field, cochlear implants, brain or cardiac stimulators, presence of a craniotomy scar)\n* Participation in another biomedical study focused on motor or overall recovery during the same period, or current exclusion period from another biomedical study\n\nHEALTHY\n\nInclusion Criteria:\n\n* Male or female aged 18 years or older on the day of inclusion.\n* Affiliated with a social security system, Universal Health Coverage (CMU), or any equivalent scheme.\n\nNon inclusion criteria\n\n\\-- Pregnant and breastfeeding women\n\n* Conditions that are life-threatening or could compromise follow-up during the study period\n* Contraindications to MRI and tACS (ferromagnetic surgical clips, ocular implants, intraocular or nervous system metallic foreign bodies, implants or metallic objects likely to concentrate the radiofrequency field, cochlear implants, brain or cardiac stimulators, presence of a craniotomy scar)\n* Participation in another biomedical study during the same period, or current exclusion period from another biomedical study",{"count":448,"type":20},45,[57],"The CERSTIM study is a physiopatholgical study investigating transcranial alternating current stimulation in stroke patients in the cerebello-motor loop.\n\nThe design is a cross over design testing two frequencies in the gamma band and one placebo.\n\nWe will use behavioural data, functional MRI, and Electroencephalography to disentangle the effect of tACS and its frequency.\n\nHealthy participants will be also recruited.",[385,452],"Healthy","2026-04-13",{"date":455,"type":34},"2026-04-16",{"date":457,"type":34},"2024-12-13",{"date":459,"type":20},"2027-12-30",{"name":40,"class":41},{"id":462,"slug":463,"hasResults":12,"nctId":464,"briefTitle":465,"officialTitle":466,"acronym":467,"eligibilityCriteria":468,"healthyVolunteers":50,"sex":469,"minAge":51,"maxAge":470,"enrollmentInfo":471,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":472,"conditions":473,"keywords":475,"overallStatus":192,"whyStopped":4,"lastUpdateSubmitDate":453,"lastUpdatePostDateStruct":479,"startDateStruct":480,"completionDateStruct":482,"leadSponsor":484,"locationsCount":42},"100534952","diagnostic-and-prognostic-markers-of-endometriosis-in-menstrual-blood-100534952","NCT06245512","Diagnostic and Prognostic Markers of Endometriosis in Menstrual Blood","RECHERCHE DE MARQUEURS DIAGNOSTIQUES ET PRONOSTIQUES DE L'ENDOMETRIOSE DANS LE SANG DES REGLES CHEZ LES FEMMES EN AGE DE PROCREER","MultiMENDo","Inclusion Criteria:\n\nFor all participants:\n\nWomen 18-45 of age who\n\n* Have their period\n* Have given their written consent\n* Have already used a menstrual cup as a method of hygienic protection\n* Residing or working in Ile de France (Paris Metropolitan area, France)\n\nFor participants with endometriosis:\n\n* diagnosis of endometriosis established by surgery or imaging (ultrasound and\u002For MRI)\n* presence of one or more painful symptoms \\> 3 on a visual scale (dysmenorrhea and\u002For dyspareunia and\u002For chronic pelvic pain) and\u002For infertility\n* for the surgery subgroup: planned surgery in the next 3 months\n\nFor participants without endometriosis:\n\n* painful symptoms \\\u003C or equal to 3 on a visual scale (for dysmenorrhea and dyspareunia and chronic pelvic pain),\n* absence of intense period pain in adolescence (leading to taking pills to control this pain and\u002For peri-menstrual school absenteeism)\n\nExclusion Criteria:\n\nFor all participants:\n\n* Autoimmune diseases\n* Chronic diseases other than endometriosis (diabetes, hypertension)\n* A person who is the subject of a judicial safeguard measure (by declaration)\n* Infectious diseases (HIV, HBV, if known)\n* History of menstrual toxic shock syndrome\n\nFor patients with endometriosis:\n\n* endometriosis surgery within the last 3 months.","FEMALE","45 Years",{"count":19,"type":20},"The goal of this observational study is to identify diagnostic and prognostic biomarkers for endometriosis using menstrual blood, an easily accessible yet overlooked biological fluid in women of reproductive age, affected or not by endometriosis\n\nThe main questions it aims to answer are:\n\n* are there relevant differences in the menstrual blood of women affected by endometriosis compared to women without endometriosis?\n* do some of these differences disappear or lessen when the disease is treated by surgery? Participants will answer questions relevant to endometriosis and provide menstrual blood 1 to 3 times (self-collected with a menstrual cup). A subgroup of participants affected by endometriosis that will undergo surgery for their regular care will provide menstrual blood before and after their surgery.\n\nResearchers will compare the menstrual blood of women with and without endometriosis, and before and after surgery to see if they can identify significant differences.",[474],"Endometriosis",[476,477,478],"biomarker","diagnosis","prognosis",{"date":455,"type":34},{"date":481,"type":34},"2024-07-31",{"date":483,"type":20},"2027-03-30",{"name":40,"class":41},{"id":486,"slug":487,"hasResults":12,"nctId":488,"briefTitle":489,"officialTitle":490,"acronym":491,"eligibilityCriteria":492,"healthyVolunteers":12,"sex":17,"minAge":493,"maxAge":494,"enrollmentInfo":495,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":497,"conditions":498,"keywords":500,"overallStatus":192,"whyStopped":4,"lastUpdateSubmitDate":453,"lastUpdatePostDateStruct":505,"startDateStruct":506,"completionDateStruct":508,"leadSponsor":510,"locationsCount":371},"100521071","long-term-follow-up-of-the-treocapa-study-treocapa-lt-100521071","NCT06064825","Long Term Follow-up of the TREOCAPA Study (TREOCAPA-LT)","Long Term Follow-up of the TREOCAPA (Prophylactic TREatment Of the duCtus Arteriosus in Preterm Infants by Acetaminophen) Study (TREOCAPA-LT)","TREOCAPA-LT","Inclusion Criteria:\n\n* were included in the TREOCAPA phase III RCT in participating centres\n* are aged between 23.5 and 27.5 months corrected age during the study period\n\nExclusion Criteria:\n\n* if the local investigator does not have up-to-date contact information allowing contact with parents\n* if the child's vital status cannot be ascertained\n* if the child is nearing the end of his life or experiencing a severe medical event as assessed by the local investigator\n* if the child has become subject to a legal protection measure preventing their ongoing participation in clinical research\n* if either parent or guardian opts out of participating\n* language barrier","23 Months","27 Months",{"count":496,"type":20},500,"The ductus arteriosus (DA) is a large channel connecting the main pulmonary trunk with the descending aorta. In extremely preterm infants, the DA frequently fails to close and this results in a condition called patent ductus arteriosus (PDA). In these patients, PDA has been associated with increased mortality and morbidity in the neonatal period, and neonatal morbidities may in turn be associated with later deficits in cognitive functioning. PDA treatment with COX inhibitors, as ibuprofen or indomethacin, aiming at closing the PDA have been associated with numerous adverse effects and failed to demonstrate significant clinical benefits. Early treatment of PDA with paracetamol (acetaminophen ) has been proposed as an alternative to COX inhibitors. The ongoing pan-European TREOCAPA phase III study (NCT04459117) is a multicentre, double-blind, randomised, placebo-controlled superiority trial that assesses prophylactic use of paracetamol to improve survival without severe neonatal morbidity until discharge from hospital in infants of 23-28 weeks of gestational age. As long-term follow-up was not planned by the TREOCAPA protocol, TREOCAPA-LT study will use an existing European research infrastructure, the RECAP Preterm platform (https:\u002F\u002Frecap-preterm.eu\u002F), to follow-up the patients enrolled in the TREOCAPA trial using a parent-report questionnaire at 2 years of corrected age.\n\nThe TREOCAPA-LT primary hypothesis is that there will be improved cognitive outcome at 2 years of corrected age in children born at less than 29 weeks of gestational age who were treated with paracetamol during the first 5 days of life in the TREOCAPA phase III trial.",[499],"Patency of the Ductus Arteriosus Acetaminophen Extreme Prematurity",[501,502,503,504],"Premature infants","persistent ductus arteriosus","paracetamol\u002Facetaminophen","long term outcome",{"date":455,"type":34},{"date":507,"type":34},"2023-12-12",{"date":509,"type":20},"2027-06",{"name":40,"class":41},{"id":512,"slug":513,"hasResults":12,"nctId":514,"briefTitle":515,"officialTitle":515,"acronym":516,"eligibilityCriteria":517,"healthyVolunteers":12,"sex":17,"minAge":51,"maxAge":4,"enrollmentInfo":518,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":520,"conditions":521,"keywords":523,"overallStatus":192,"whyStopped":4,"lastUpdateSubmitDate":453,"lastUpdatePostDateStruct":527,"startDateStruct":529,"completionDateStruct":531,"leadSponsor":533,"locationsCount":42},"100504587","mechanism-of-action-of-interferon-in-the-treatment-of-myeloproliferative-neoplasms-100504587","NCT05850273","Mechanism of Action of Interferon in the Treatment of Myeloproliferative Neoplasms","IFN&SMP","Inclusion Criteria:\n\n1. Adult male or female 18 years of age or older\n2. Diagnosis of MPN has been previously established by the referring physician and that physician will have decided to treat with pegylated IFN. Patients will be treated or untreated at the time of inclusion and may be newly diagnosed patients.\n3. These patients will be affiliated with or benefit from a social security plan\n4. For all these patients an additional 20-40 mL will be collected except for some PV patients who are treated conventionally by phlebotomy. In this case, we will collect blood bags from these patients. The volumes vary between 300 and 450 mL of blood depending on the weight and size of the patients.\n5. We will also include in this protocol any patient whose MPN, either PV, TE or MF, will have progressed to acute leukemia (AL) during treatment. These will be patients with AP of MPN (MPN can also progress to acute myeloid leukemia (AML) by acute transformation (AT) of MPN).\n6. Patient with signed informed consent\n\nExclusion Criteria:\n\n1. The non-inclusion criterion concerns the anemia that some MF patients may suffer from. Therefore, patients with anemia (Hb\\\u003C10g) or transfusion dependency (≥ 1 packed red blood cell per month) at the time of the referral monitoring visit are not included in the research.\n2. Persons under court protection, guardianship or curatorship",{"count":519,"type":20},80,"Classical BCR-ABL-negative myeloproliferative neoplasms (MPN) include: Polycythemia Vera (PV), Essential Thrombocythemia (ET) and Primary Myelofibrosis (PMF). They are myeloid malignancies resulting from the transformation of a multipotent hematopoietic stem cell (HSC) caused by mutations activating the JAK2\u002FSTAT pathway. The most prevalent mutation is JAK2V617F. Type 1 and Type 2 calreticulin (CALR) and thrombopoietin receptor (MPL) mutations are also observed in ET and PMF. Additional non-MPN mutations affecting different pathways are also found, particularly in PMF, and are involved in disease initiation and\u002For in phenotypic changes and \u002For disease progression and\u002For response to therapy.\n\nThere is an obvious and urgent need for an efficient therapy for MPN. In particular, PMF remain without curative treatment, except allogeneic HSC transplantation and JAK inhibitors have limited effects on the disease outcome. Among novel therapeutic approaches, Peg-IFNα2a (IFN) is the most efficient harboring both high rates of hematological responses in JAK2V617F and CALRmut MPN patients and some molecular responses mainly in JAK2V617F patients including deep molecular response (DMR). Nevertheless, several studies, including our own, have demonstrated that the IFN molecular response in CALRmut patients is heterogeneous and overall much lower than in JAK2V617F patients. Moreover, some JAK2V617F MPN patients do not respond to IFN, and DMR is only observed in around 20% of JAK2V617F patients. Finally, long-term treatments are needed (2-5 years) to obtain a DMR, jeopardizing its success due to possible long-term toxicity.\n\nThe underlying reasons for failure, drug resistance, heterogeneous molecular response in CALRmut patients and the long delays for DMR in JAK2V617F patients remain unclear, largely because the mechanisms by which IFNα targets MPN malignant clones remain elusive.\n\nSignificant improvement of IFN efficacy cannot be achieved without basic and clinical research. Hence our two lines of research are to\n\n* Understand how IFNα specifically targets neoplastic HSCs\n* Predicting and improving patient response during IFNα therapy",[522],"Myeloproliferative Neoplasm",[524,525,526],"interferon alpha","Hematopoietic stem cell","mechanism of action",{"date":528,"type":34},"2026-04-14",{"date":530,"type":34},"2023-03-16",{"date":532,"type":20},"2033-03-16",{"name":40,"class":41},{"id":535,"slug":536,"hasResults":12,"nctId":537,"briefTitle":538,"officialTitle":538,"acronym":539,"eligibilityCriteria":540,"healthyVolunteers":12,"sex":17,"minAge":51,"maxAge":4,"enrollmentInfo":541,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":543,"conditions":544,"keywords":550,"overallStatus":192,"whyStopped":4,"lastUpdateSubmitDate":453,"lastUpdatePostDateStruct":551,"startDateStruct":552,"completionDateStruct":554,"leadSponsor":556,"locationsCount":42},"100487136","chronic-hepatopathies-associated-with-alcohol-consumption-and-metabolic-syndrome-100487136","NCT05623150","CHronic Hepatopathies Associated With ALcohol Consumption aNd metAbolic Syndrome","CHALNA2","Inclusion Criteria:\n\n* Criteria common to all patients:\n\n  1. Affiliation to French social security.\n  2. Male or female ≥ 18 years of age\n  3. Patients able to receive and understand information about the research and to give written informed consent duly signed by the patient and the investigator (at the latest on the day of inclusion and before any examination necessary for the research).\n* Patients in the NAFLD group with HCC:\n\n  1. Alcohol consumption ≤ 30 g pure alcohol\u002Fd (or 210 g pure alcohol\u002Fweek) for men and ≤ 20 g pure alcohol\u002Fd (140 g pure alcohol\u002Fweek) for women.\n  2. Decision, less than 3 months old, of liver biopsy of the suspected HCC nodule and non-tumour liver tissue performed as a clinical routine.\n  3. No systemic treatment for HCC within 6 months prior to inclusion.\n* Patients in the NAFLD group without HCC:\n\n  1. Alcohol consumption ≤ 30 g pure alcohol\u002Fd (or 210 g pure alcohol\u002Fweek) for men and ≤ 20 g pure alcohol\u002Fd (140 g pure alcohol\u002Fweek) for women.\n  2. Decision of less than 3 months of a liver biopsy performed as a clinical routine. Biopsy will be motivated by liver function disturbance(s) and\u002For ultrasound steatosis given the lack of validated non-invasive tests or the lack of accuracy (grey areas) of available non-invasive tests for the diagnosis of necro-inflammation and\u002For fibrosis in some of these patients.\n* Patients in the alcohol-related liver disease group with HCC:\n\n  1. Alcohol consumption \\> 30 g pure alcohol\u002Fd (or 210 g pure alcohol\u002Fweek) for men and \\> 20 g pure alcohol\u002Fd (140 g pure alcohol\u002Fweek) or binge drinking\n  2. Decision within 3 months of liver biopsy of suspected HCC nodule and non-tumour liver tissue performed as part of clinical routine\n  3. No systemic treatment for HCC within 6 months prior to inclusion.\n* Patients in the alcohol-related liver disease group without HCC:\n\n  1. Alcohol consumption \\> 30 g pure alcohol\u002Fd (or 210 g pure alcohol\u002Fweek) for men and \\> 20 g pure alcohol\u002Fd (140 g pure alcohol\u002Fweek) or binge drinking\n  2. Decision of less than 3 months for a liver biopsy to be performed as a clinical routine. Biopsy will be motivated by liver balance disturbance(s) and\u002For ultrasound steatosis given the lack of validated non-invasive tests or the lack of accuracy (grey areas) of available non-invasive tests for the diagnosis of necro-inflammation and\u002For fibrosis in some of these patients.\n\nExclusion Criteria:\n\n1. Positive HIV serology\n2. Patients with detectable hepatitis C viral load\n3. Presence of Hbs antigen\n4. History of autoimmune hepatitis type 1 or 2, primary biliary cholangitis, primary sclerosing cholangitis, Wilson's disease, genetic haemochromatosis homozygous, alpha1 anti-trypsin deficiency\n5. Long-term use of methotrexate, corticosteroids, anti-Tumor Necrosis Factor cyclosporine, tacrolimus\n6. History of solid organ transplantation or bone marrow transplantation\n7. Cancerous disease in the process of being treated, except for skin cancer (excluding melanoma)\n8. Patients under legal protection or unable to express their consent,\n9. Pregnant or breastfeeding women",{"count":542,"type":20},710,"The aim is to determine the metabolic factors, host immune factors, and medical imaging data associated with the development of HepatoCellular Carcinoma (HCC) in patients with alcohol-related liver disease or dysmetabolic steatosis\u002FNon-Alcoholic SteatoHepatitis.\n\nThe investigators will include patients with and without cirrhosis in order to identify early molecular mechanisms involved in the development of HCC especially in non-cirrhotic patients.",[545,546,547,548,549],"Non-Alcoholic Fatty Liver Disease","Non-Alcoholic Steatohepatitis","Alcohol-related Liver Disease","Cirrhosis, Liver","Hepatocellular Carcinoma",[545,546,547,548,549],{"date":455,"type":34},{"date":553,"type":34},"2022-12-06",{"date":555,"type":20},"2032-03",{"name":40,"class":41},{"id":558,"slug":559,"hasResults":12,"nctId":560,"briefTitle":561,"officialTitle":561,"acronym":562,"eligibilityCriteria":563,"healthyVolunteers":12,"sex":17,"minAge":51,"maxAge":4,"enrollmentInfo":564,"targetDuration":4,"studyType":55,"phases":566,"briefSummary":567,"conditions":568,"keywords":570,"overallStatus":192,"whyStopped":4,"lastUpdateSubmitDate":574,"lastUpdatePostDateStruct":575,"startDateStruct":577,"completionDateStruct":579,"leadSponsor":581,"locationsCount":582},"100559910","role-of-high-throughput-whole-genome-sequencing-for-the-diagnosis-and-care-of-atypical-diabetes-100559910","NCT06570278","Role of High-Throughput Whole Genome Sequencing for the Diagnosis and Care of Atypical Diabetes","GLUCOGEN","Inclusion Criteria:\n\n* Subjects ≥18 years with confirmed diabetes mellitus according to WHO criteria (World Health Organization: Definition and diagnosis of diabetes mellitus and intermediate hyperglycemia: Report of a WHO\u002FIDF Consultation. Geneva, World Health Org., 2006.)\n* Age ≤ 45 years at diabetes diagnosis\n* Body mass index ≤ 35 kg\u002Fm² at diabetes diagnosis\n* Negative results of specific antibodies determination (GAD65, IA2, ZnT8) until the inclusion visit\n* Presenting atypical diabetes defined by at least one of the following:\n* Exocrine pancreatic disease\n* Familial history: diabetes diagnosed in a parent, child or sibling\n* Notion of familial consanguinity\n* Syndromic clinical features (dysmorphy, developmental delay, mental retardation…) or unusual abnormalities\u002Ffeatures that are not part of diabetic complications or co-morbidities;\n* Early occurrence of microvascular complications (≤ 5 years after diabetes diagnosis)\n* Major insulinopenia at diagnosis (C peptide \\\u003C 0.2 nmol\u002FL and\u002For documented ketosis)\n* Patient who conserved endogenous insulin secretion (positive C peptide value) but a need for insulin therapy initiation during the first year following diagnosis due to therapeutic failure of well conducted therapeutic intensification\n* Stated willingness to comply with all study procedures and availability for the duration of the study\n* Patient with a social security number in compliance with the French law (dispositions relatives aux recherches impliquant la personne humaine prévues aux articles L 1121-1 et suivants du Code de la Santé Publique)\n* Signed and dated informed consent form\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding woman,\n* Any contraindication to the study exams including known allergies or contraindication to contrasts for the scan\n* Patient with known monogenic diabetes (defined as identification of class 4 and 5 variants according to ACMG)\n* First or second-degree relatives with monogenic diabetes established by molecular genetics (class 4 and 5 variants according to ACMG)\n* Patient with known secondary diabetes (i.e. endocrine disorders such as Cushing syndrome, pancreatectomy, drug-induced diabetes)\n* Patient who had a bone marrow transplant\n* Any condition which in the Investigator's opinion makes it undesirable for the subject to participate in the trial or which would jeopardize compliance with the protocol,\n* Individuals under legal protection (sauvegarde de justice).",{"count":565,"type":20},1020,[57],"The main objective of the study is to assess the contribution of whole genome sequencing (WGS) coupled with a multidisciplinary conciliation meeting (MCM) on diagnosis of atypical forms of diabetes compared to an in-silico analysis of a panel of validated genes (ISApanel), corresponding to current practice, in a randomized trial.\n\nNotably, the questions it aims to answer are:\n\n* The feasibility of the WGS coupled with MCM on diagnosis of atypical forms of diabetes,\n* The contribution of WGS coupled with MCM on number of genetic alterations likely causal of diabetes identified and with a modification in care and support of patients.\n\nAfter inclusion and sampling for genotyping, patients will be followed for 5 years.\n\nThe target population is 1020 adults with atypical diabetes for whom it is possible to obtain a blood sample.",[569],"Diabetes Mellitus",[571,572,573],"Next generation sequencing genome","Diagnostic study","Medico-economic study","2026-04-08",{"date":576,"type":34},"2026-04-09",{"date":578,"type":34},"2024-10-30",{"date":580,"type":20},"2034-11",{"name":40,"class":41},26,{"id":584,"slug":585,"hasResults":12,"nctId":586,"briefTitle":587,"officialTitle":588,"acronym":589,"eligibilityCriteria":590,"healthyVolunteers":50,"sex":17,"minAge":591,"maxAge":592,"enrollmentInfo":593,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":595,"conditions":596,"keywords":4,"overallStatus":192,"whyStopped":4,"lastUpdateSubmitDate":574,"lastUpdatePostDateStruct":598,"startDateStruct":599,"completionDateStruct":601,"leadSponsor":603,"locationsCount":340},"100443435","crosstalk-between-mucosal-associated-invariant-t-mait-cells-and-the-gut-microbiota-and-mucosa-in-the-development-of-type-1-diabetes-in-children-100443435","NCT05054361","Crosstalk Between Mucosal-Associated Invariant T (MAIT) Cells and the Gut Microbiota and Mucosa in the Development of Type 1 Diabetes in Children","Crosstalk Between Mucosal-Associated Invariant T Cells and the Gut Microbiota and Mucosa in the Development of Type 1 Diabetes in Children","MAIT-DT1","Inclusion Criteria:\n\nRecent onset group\n\n* age \\> 12 months and \\\u003C 15 years\n* recently diagnosed type 1 diabetes according ISPAD criteria\n\nAt risk subjects:\n\n* age \\> 12 months and \\\u003C 15 years\n* siblings of type 1 diabetic patient\n* HLA DR3 and DR4 positive\n\nControl subjects:\n\n* age \\> 12 months and \\\u003C 15 years\n* no HLA associated with high risk type 1 diabetes\n* no antibodies against pancreas antigenes\n\nControl subjects for UGI endoscopy:\n\n* age \\> 12 months and \\\u003C 15 years\n* suspicion of coeliac disease or gastritis\n\nExclusion Criteria:\n\nFor all groups:\n\n* no health care insurance\n* parents or tutors unable to sign the consent\n* personal history of autoimmune disease and\u002For inflammatory disease except from T1D for RD and CE groups\n* use of corticosteroids during the month before inclusion\n* pregnant subjects\n* medical contraindication of anesthetic topics\n\nFor control subjects for UGI endoscopy control and Recent onset-endoscopy group:\n\n* age below 8 years for Recent onset-endoscopy group\n* age below 4 for UGI endoscopy control group\n* cardiac or respiratory insufficiency, cardiac rhythm disorders, coagulation disease, patients treated with anticoagulant or antiaggregant drug\n* history of allergy to anesthetic drug","12 Months","15 Years",{"count":594,"type":20},180,"To investigate in a prospective way changes in Mucosal-Associated Invariant T (MAIT) cells frequency, phenotype and function in link with the gut microbiota, gut integrity and the presence of Coxsackie virus B in two cohorts of pediatric patients: patients with a high genetic risk of type 1 diabetes and pediatric patients with recently diagnosed T1D by comparison with control subjects\n\nTasks:\n\n1. To measure blood MAIT cells frequency, phenotype and function in the three cohorts\n2. To analyze gut microbiota and the presence of Coxsackie B enterovirus (CVB) and their impact on MAIT cell function\n3. To evaluate gut integrity and analyze the gut mucosa\n4. To integrate all the data obtained with T1D development and evolution",[597],"Type1diabetes",{"date":453,"type":34},{"date":600,"type":34},"2022-01-01",{"date":602,"type":20},"2027-08-14",{"name":40,"class":41},{"id":605,"slug":606,"hasResults":12,"nctId":607,"briefTitle":608,"officialTitle":609,"acronym":610,"eligibilityCriteria":611,"healthyVolunteers":12,"sex":17,"minAge":51,"maxAge":4,"enrollmentInfo":612,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":614,"conditions":615,"keywords":618,"overallStatus":192,"whyStopped":4,"lastUpdateSubmitDate":623,"lastUpdatePostDateStruct":624,"startDateStruct":626,"completionDateStruct":628,"leadSponsor":630,"locationsCount":42},"100583082","genetic-of-intellectual-deficiency-and-autism-spectrum-disorders-radico-genida-100583082","NCT06871696","Genetic of Intellectual Deficiency and Autism Spectrum Disorders (RaDiCo-GenIDA)","Genetic of Intellectual Deficiency and Autism Spectrum Disorders","RaDiCo-GenIDA","Inclusion Criteria:\n\n* Be a voluntary adult (aged 18 or older)\n* Be a family member (i.e., mother\u002Ffather) of patients with intellectual disabilities and\u002For autism spectrum disorders of known genetic origin. This includes monogenic causes as well as recurrent copy number variations (CNVs) such as deletions or duplications. Note: we also allow adult patients to participate directly if they wish and have the capacity to do so.\n* Have knowledge of the genetic cause behind intellectual disabilities or autism spectrum disorders. An exception to this rule is possible for patients with a syndrome that includes intellectual disabilities or autism spectrum disorders, and for whom genetic investigation is considered, with the approval of the project's scientific council (which will define the syndromes eligible for this exception).\n* Have the intellectual and material capabilities to complete an internet questionnaire.\n* Have read the information sheet regarding the study and agreed to the general conditions of participation in the study.\n\nThere are no restrictions based on age, gender, or potential comorbidities of the individual themselves.\n\nExclusion Criteria:\n\n* Patients affected by the presence of intellectual disability and\u002For an autism spectrum disorder of unknown genetic origin will not be able to participate in the study, except with the exception mentioned in the previous chapter.\n* It is requested that only adults enter data. However, the collected data may pertain to a minor (in the case of a parent entering data about their minor child)",{"count":613,"type":20},1000,"The aim of this observational study is to develop an alternative database model for genetically originated intellectual disabilities. This model will take the form of an online cohort study, where the majority of clinical information will be provided by the families of the patients. Questionnaires developed by professionals but formulated in a way understandable to families will be used to gather this information.\n\nSpecifically, this study aims to collect relevant information for personalized medical management. This includes understanding the risks of specific pathological complications and potential iatrogenic effects of symptomatic treatments. The primary goal is to establish groups of individuals with intellectual disabilities and\u002For autism spectrum disorders (ASD) sharing the same genetic mutation. This approach will provide a better understanding of the natural history of the disease and associated comorbidities.\n\nIt is important to note that this project will only focus on patients for whom the identification of the causal mutation or penetrant copy number variation (CNV) has been determined. It excludes individuals for whom the cause of intellectual disability is unknown.\n\nThis approach will contribute to a better understanding of the genetic aspects of intellectual disabilities and ASD, while facilitating more targeted and personalized medical care for the affected patients.",[616,617],"Genetic of Intellectual Deficiency","Autism Spectrum Disorder",[619,620,621,622],"Autism Spectrum","Intellectual Disability","Rare disease","Genetic origin","2026-03-10",{"date":625,"type":34},"2026-03-11",{"date":627,"type":34},"2016-11",{"date":629,"type":20},"2026-11",{"name":40,"class":41},{"id":632,"slug":633,"hasResults":12,"nctId":634,"briefTitle":635,"officialTitle":635,"acronym":636,"eligibilityCriteria":637,"healthyVolunteers":50,"sex":17,"minAge":638,"maxAge":185,"enrollmentInfo":639,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":641,"conditions":642,"keywords":4,"overallStatus":192,"whyStopped":4,"lastUpdateSubmitDate":623,"lastUpdatePostDateStruct":644,"startDateStruct":645,"completionDateStruct":647,"leadSponsor":649,"locationsCount":42},"100542926","uncovering-the-cognitive-and-neural-mechanisms-underlying-cognitive-time-100542926","NCT06349213","Uncovering the Cognitive and Neural Mechanisms Underlying Cognitive Time","TIMES","Inclusion Criteria:\n\n1. Membership of a social security scheme or beneficiary of such a scheme.\n2. At least 7 years' schooling.\n3. Acceptance and signature of the informed consent form\n4. Fluency in French (as assessed by the project leader)\n5. Age between 20 and 35 years inclusive for young healthy subjects, and between 60 and 85 years inclusive for elderly healthy subjects.\n6. Effective contraception for women of childbearing age: Contraception will be considered effective from the moment the participant declares taking an oral contraceptive, the presence of an IUD, diaphragm or contraceptive implant, or the performance of a tubal ligation or sterilisation.\n7. Absence of global cognitive deficit attested by a score on the MOCA scale greater than or equal to 26\u002F30.\n\nExclusion Criteria:\n\n1. Persons under guardianship, curators or safeguard of justice.\n2. Pregnant women, women in labor and nursing mothers\n3. Chronic neurological conditions\n4. Uncorrected visual difficulties\n5. Encephalitis\n6. Endocrine or liver disease\n7. History of head trauma with loss of consciousness lasting more than one hour\n8. History of cancer in the last 5 years, with the exception of squamous cell carcinoma of the skin\n9. Presence or history of chronic alcoholism or drug addiction\n10. Presence of clinically significant major psychiatric disorders (according to DSM-IV-TR criteria) or symptoms that could affect the participant's ability to complete the research.\n11. Use of medications that may modulate the dopaminergic system (psychotropic, with the exception of sleeping pills or occasional use of anxiolytics, as decided by the principal investigator).\n12. Contraindications to MRI examination (pregnancy; pacemaker or neurosensory stimulator or implantable defibrillator; clip on an aneurysm or clip on a vascular malformation of the brain; intraocular or cerebral ferromagnetic foreign body; prosthesis or mobilizable ferromagnetic metal object or splinter; cochlear implant ; peripheral stimulator; neurosurgical ventriculoperitoneal shunt valves; permanent eyelid or lip make-up; jewelry or piercing that cannot be removed; certain tattoos depending on the type of ink, size and location; automated injection devices such as insulin pumps, blood glucose sensors, claustrophobia).\n13. Radiotracer contraindications: Hypersensitivity to product excipients, chronic alcoholism, kidney disease.\n14. Participation in research involving exposure to ionizing radiation (nuclear medicine or radiology examinations) in the year preceding inclusion or during a period of exclusion from other research.","20 Years",{"count":640,"type":20},130,"Time processing, the ability to process and encode temporal information, is essential for cognitive functioning and for a large number of daily life activities. In particular, the processing of durations of several seconds is central to cognition, impaired in several pathologies, and has been associated with cognitive changes with advancing age. While behavioral studies have been conducted to specify the neural bases of temporal cognition and their association with other cognitive functions, the mechanisms underlying age-related changes, and individual differences, remain unknown. The project will characterize ageing effects on timing mechanisms and their neural underpinnings. Building on recent advances from neuroscience and age-related cognitive changes, the project focuses on the precision of duration processing, that declines with age, and the associated neural bases. Participants will perform a duration judgement task while (a) electroencephalography, and (b) functional magnetic resonance imaging activity are simultaneously recorded to investigate age effects on structural and functional network connectivity. In addition, striatal dopamine will be measured using a FDOPA PETscan. Evaluation of other temporal cognition processes and general cognition will also be performed. This combination offers a unique opportunity to accurately specifying the neurophysiological underpinning of aging effects on time processing changes. This project will further our understanding of the variability of cognitive performance with advancing age, and contribute to identifying new measures of temporal impairments.",[643],"Healthy Aging",{"date":625,"type":34},{"date":646,"type":34},"2024-11-20",{"date":648,"type":20},"2030-11-01",{"name":40,"class":41},""]